It is made available under a CC-BY-NC-ND 4.0 International license .

1	An Updated Systematic Review and Meta-Analysis of Mortality, Need for ICU admission,
2	Use of Mechanical Ventilation, Adverse effects and other Clinical Outcomes of Ivermectin
3	Treatment in COVID-19 Patients
4	*Smruti Karale, MBBS ¹ ; *Vikas Bansal, MBBS, MPH ² ; Janaki Makadia, MBBS ³ ; Muhammad
5	Tayyeb, MD ⁴ ; Hira Khan, MBBS ⁵ ; Shree Spandana Ghanta, MBBS ⁶ ; Romil Singh, MBBS ⁷ ;
6	Aysun Tekin, MD ⁸ ; Abhishek Bhurwal, M9 ⁸ ; Hemant Mutneja, MD ¹⁰ ; Ishita Mehra, MBB ¹¹ ;
7	Rahul Kashyap, MBBS, MBA ⁸
8	¹ Medical Graduate, Government Medical College Kolhapur, Kolhapur, India
9	² Division of Pulmonary and Critical Care Medicine, Mayo Clinic Rochester, MN, USA
10	³ Medical Graduate, GMERS Medical College, Vadodara, Gujarat, India
11	⁴ Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ, USA
12	⁵ Department of Neurology, Allegheny General Hospital, Pittsburgh, PA, USA
13	⁶ Department of Internal Medicine, St. Elizabeth's Medical Center, Boston, MA, USA
14	⁷ Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, PA
15	⁸ Department of Anesthesiology and Perioperative Medicine, Mayo Clinic Rochester, MN, USA
16	⁹ Department of Gastroenterology and Hepatology, Rutgers Robert Wood Johnson School of
17	Medicine, New Brunswick, NJ, USA
18	¹⁰ Division of Gastroenterology, Cook County Hospital, Chicago, Illinois

19 ¹¹Department of Internal Medicine, North Alabama Medical Center, Florence, AL, USA

It is made available under a CC-BY-NC-ND 4.0 International license .

20 Corresponding Author:

21 Vikas Bansal, MBBS, MPH

- 22 Assistant Professor of Medicine
- 23 Division of Pulmonary and Critical Care Medicine
- 24 Mayo Clinic, Rochester, MN- 55905
- 25 Email: bansal.vikas@mayo.edu
- 26 Phone: +1-507-398-1595
- 27 Word count: Abstract: 250; Manuscript: 5041
- **Tables:** 0 main, 8 supplemental
- 29 Figures: 6 main, 31 supplemental
- 30 **Conflicts of Interest:** None of the authors have reported any conflicts of interest.
- 31 **Financial Support:** There is no financial disclosure related to this study.
- 32 Author Contribution: *Authors 1(SK) and 2(VB) contributed equally in defining the study
- 33 outline and manuscript writing. Data review and collection were done by HK, JM, SG, RS, SK,
- and MT; statistical analysis done by SK, VB, and AB. Quality assessment of studies was done by
- 35 AT, JM, HK, MT, SK, VB and GRADE quality rating was done by AB, HM and VB. Study
- 36 design, distribution of articles for critical review done by SK, VB and RK. Final approval was
- 37 received from all authors. SK and VB is the guarantor of the paper, taking responsibility for the
- 38 integrity of the work as a whole, from inception to published article.

It is made available under a CC-BY-NC-ND 4.0 International license .

30	Acknowledgment:	We acknowledge	Dr Anant Mohan	Dr Asma A	sohar Dr	Flavio Cadegiani
39	Acknowledgment.	WE aCKNOWIEUge	DI. Analit Monali,	DI. Asilia A	Asgilal, DI.	riavio Caucgiain,

- 40 Dr. Houssam Raad, Dr. José Morgenstern, Dr. Morteza Niaee, Dr. Nasir Afsar, Dr. Nurullah
- 41 Okumus, Dr. Olufemi Babalola, Dr. Pablo Méndez-Hernández, Dr. Ravi Kirti, Dr.Ravindra
- 42 Ghooi, Dr. Reaz Mahmud and Dr. Tasnim Ahsan for their correspondence and contribution.
- 43 Keywords: Ivermectin, COVID-19, SARS-CoV-2, Mortality, ICU, Mechanical ventilation,
- 44 adverse effect, Systematic Review, Meta-analysis
- 45 Short tile: Clinical Outcomes Associated with Ivermectin use in COVID-19: An Updated
- 46 Systematic Review And Meta-Analysis
- 47 Highlights

48 What We Already Know about This Topic

- 49 1. COVID-19 is an ongoing global pandemic, for which Ivermectin has been tried on a
- 50 therapeutic and prophylactic basis.
- 2. Results from several clinical trials and observational studies suggest that Ivermectin may
 improve survival and clinical outcomes with a good safety profile when compared with
- 53 other treatments; however, the current evidence is limited. .

54 What This Article Tells Us That Is New

- This systematic review and meta-analysis provide a summary of the latest literature on
 the efficacy and safety of Ivermectin use for COVID-19.
- 57 2. Based on our analysis of the latest evidence, we found that Ivermectin's benefit in
- 58 reducing mortality cannot be concluded with confidence . However, as an adjuvant

- 59 therapy it may help reduce the need for hospitalization, duration for viral clearance while
- 60 increasing the likelihood of achieving viral clearance.
- 61 3. We need more high-quality data for conclusive evidence regarding the benefit of
- 62 Ivermectin in reducing the need for ICU admissions ,mechanical ventilation and duration
- 63 of hospital stay in COVID-19 patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

64 List of abbreviations

- 65 **ARDS:** Acute respiratory distress syndrome
- 66 **CDC:** Centers for Disease Control and Prevention
- 67 COVID-19: Coronavirus Disease 2019
- 68 **DNA:** Deoxyribonucleic Acid
- 69 EMA: European Medicines Agency
- 70 FDA: Food and Drug Administration
- 71 ICU: Intensive Care Unit
- 72 **IRB:** Institutional Review Board
- 73 NIH: National Institutes of Health
- 74 **RCT:** Randomized controlled trial
- 75 **RNA:** Ribonucleic Acid
- 76 **RT-PCR:** Reverse Transcription Polymerase Chain Reaction
- 77 **IMP:** Importin
- 78 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2
- 79 WHO: World Health Organization

It is made available under a CC-BY-NC-ND 4.0 International license .

80 Abstract

Importance: Repurposing Ivermectin, a known anti-parasitic agent, for treating COVID-19 has
demonstrated positive results in several studies. We aim to evaluate the benefit and risk of
Ivermectin in COVID-19.
Methods: We conducted a systematic search for full-text manuscripts published from February
1, 2020, to August 15th, 2021 focusing on Ivermectin therapy against COVID-19. The primary

86 outcomes were mortality, need for intensive care unit (ICU) admission; secondary outcomes

87 were - adverse effects, need for mechanical ventilation, viral clearance, time to viral clearance,

need for hospitalization, and length of hospital stay. Random-effects models were used for all

analyses.

90 **Results:** We included a total of 52 studies (n=17561) in the qualitative analysis, out of these, 44

studies (n=14019) were included in the meta-analysis. In the mortality meta-analysis (N=29),

92 odds of death were lower in the Ivermectin-arm compared to control (OR 0.54, p=0.009).

93 Although lower odds of mortality were observed in various subgroup analyses of RCTs, they did

94 not reach statistical significance: therapeutic RCTs: mild-moderate COVID-19 (OR 0.31,

95 p=0.06), therapeutic RCTs: severe/critical COVID-19 (OR 0.86, p=0.56), inpatient RCTs: mild-

96 moderate COVID-19 (OR 0.18, p=0.08), inpatient RCTs: severe/critical COVID-19 (OR 0.86,

97 p=0.56). Ivermectin, mostly as adjuvant therapy, was associated with higher odds of viral

98 clearance (N=22) (OR 3.52, p=0.0002), shorter duration to achieve viral clearance (N=8) (MD -

4.12, p=0.02), reduced need for hospitalization (N=6) (OR 0.34, p=008).

100 **Conclusion:** Our meta-analysis suggests that the mortality benefit of Ivermectin in COVID-19 is

101 uncertain. But as adjuvant therapy, Ivermectin may improve viral clearance and reduce the need

102 for hospitalization.

It is made available under a CC-BY-NC-ND 4.0 International license .

103 Introduction

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 disease 104 a global pandemic¹. Today, on September 9,2021, there are about >222 million confirmed cases 105 worldwide and >4.6 million deaths due to COVID- 19^2 . Patients infected with SARS-COV-2, the 106 107 causative Coronavirus, exhibit a spectrum of clinical presentations ranging from asymptomatic to severely critical and multiple risk factors are involved in the prognosis of the disease³⁻⁸. To guide 108 decision-making for this multi-system disease⁸⁻¹⁷, a variety of treatment modalities have been 109 proposed and evaluated¹⁸⁻²³. However, the evidence for the risk-benefit ratio of most of these 110 111 treatments remains unclear.

Ivermectin has held an excellent safety record in humans as an antiparasitic agent for 112 over three decades²⁴. Apart from its established activity against several parasites, Ivermectin has 113 demonstrated antiviral activity against many RNA and DNA viruses in vivo and against a few in 114 vitro by targeting specific proteins²⁵. One such plausible mechanism against RNA viruses is the 115 116 inhibition of importin (IMP) α/β Integrase, thus blocking viral entry into the nucleus and the ensuing suppression of the cell's anti-viral response²⁵⁻²⁸. Moreover, it exhibited anti-bacterial, 117 anti-inflammatory, and anti-cancer effects^{24,29,30}. An Australian study demonstrated the 118 effectiveness of Ivermectin in inhibiting SARS-COV2 in-vitro³¹. Subsequently, several 119 120 Ivermectin-based clinical trials and observational studies conducted globally showed mostly positive results³²⁻³⁵. Some countries have incorporated this therapy in their COVID-19 121 guidelines³⁶⁻³⁹. Only a month after this authorization, Peru witnessed a record drop of 25% in 122 123 COVID-19 related mortality⁴⁰.

Dr. Satoshi Ōmura, who was among the scientists that won the Nobel prize for the
discovery of Ivermectin, highlighted the need to develop a drug that arrests the early stage of

It is made available under a CC-BY-NC-ND 4.0 International license .

126 viral replication in COVID-19⁴¹. Repurposing Ivermectin, a low-cost drug may help bypass the

127 time and funds needed to develop and test novel therapies. The lack of robust evidence has been

128 a major hindrance in the large-scale approval of Ivermectin. The available studies are

129 methodologically diverse and mostly under-powered while few report conflicting results.

130 Therefore, we intend to systematically review the latest literature and plan to perform a meta-

analysis to overcome some of the individual study biases.

132 Methods:

133 Search Method and strategy

We conducted a comprehensive literature search for studies mentioning the use of Ivermectin in COVID-19 from February 1, 2020 till August 15, 2021 (Figure 1). We screened all titles and abstracts identified by preliminary search for eligible studies and manually searched references of included articles for additional studies. Then we analyzed full-text manuscripts of included studies according to the protocol of Systematic Review and Meta-Analysis (PRISMA) guidelines.

140 Eligibility Criteria

We included studies reporting outcomes of mortality, ICU admission, mechanical
ventilation, adverse-effects, viral clearance, hospitalization with therapeutic Ivermectin treatment
against COVID-19. We excluded studies focusing on pregnant females, in- vitro studies, metaanalyses, case reports and case series <5 patients.

145 Study selection and data extraction

The extracted data was tabularized in Microsoft Excel with following parameters: author,
country of study, study design, number of patients, Ivermectin regimen, concomitant treatment,

148 efficacy outcomes and adverse effects. The included data was checked for accuracy by all

It is made available under a CC-BY-NC-ND 4.0 International license .

149 authors and disagreements were resolved through consensus and after input from a third 150 reviewer. IRB approval was exempted because data was extracted from publicly available studies. We also analyzed raw data files or supplemental files of studies by Cadegiani⁴² and 151 Lima-Morales et al⁴³ for outcomes of cases receiving Ivermectin, Niaee et al⁴⁴ for clinical 152 severity based mortality data and duration of hospital stay, Choudhary et al³⁵ for time for viral 153 clearance, Mahmud et al⁴⁵ for need for hospitalization, Ghooi et al⁴⁶ for mortality in Ivermectin 154 receiving patients, Samaha et al⁴⁷ for viral clearance. In Cadegiani et al's study⁴², we considered 155 'CG1' as control group because only this sample was demographically comparable to the 156 157 treatment group. Additionally, we compiled all ongoing clinical trials on Ivermectin from clinicaltrials.gov (e-Table-8). We excluded the study by Elgazzar et al⁴⁸ because it was retracted. 158 Outcomes 159

The primary outcome was defined as mortality benefit with Ivermectin therapy in
COVID-19 and need for ICU admission. The secondary outcomes were need for mechanical
ventilation ,adverse effects of Ivermectin, viral clearance and time to achieve viral clearance,
need for hospitalization and duration of hospital stay.

164 Statistical analysis

Primary and Secondary outcomes were quantitatively analyzed by Review Manager (RevMan) Version 5.4 for windows⁴⁹ and Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA)⁵⁰ was used for pooled-analysis. Random-effects model was used for both⁵¹. Raw data for outcomes and non-events from each study were used to calculate crude odds ratio (OR) with 95% confidence intervals (CI) for each study. The Cochrane Q and I² statistics were calculated to assess heterogeneity between studies⁵¹. I² <25% were interpreted as low-level heterogeneity⁵¹. We performed subgroup analysis by study design to decrease inherent

selection bias in observational studies⁵¹. Probability of publication bias was assessed with funnel plot using Egger's tests⁵¹ (e-Figure 15-31). If there was statistical heterogeneity in results, further sensitivity analysis was conducted to determine the source of heterogeneity by excluding each study. After significant heterogeneity was excluded, random-effects model was used for metaanalysis. For sensitivity analysis, if we found heterogeneity to be similar with different studies' exclusion, we chose to present the result with lowest odd's ratio. P-value <0.05 (2-sided) was considered statistically significant⁵¹.

179 Risk of Bias and Quality assessment

Clinical trials were evaluated using Cochrane risk of bias tool⁵² (e-Table 2) and 180 181 correlation of quality measures with estimates of treatment effects in meta-analyses of randomized controlled trials tool⁵³ (e-Table 3) was used for quality assessment. We used NIH 182 quality assessment Tool for case series⁵⁴ (e-Table 4), case-control (e-Table 5), or cohort studies 183 184 (e-Table 6). NIH quality assessment tools were based on quality assessment methods, concepts, and other tools developed by researchers in the Agency for Healthcare Research and Quality 185 186 (AHRQ), Cochrane Collaboration, USPSTF, Scottish Intercollegiate Guidelines Network, and National Health Service Centre for Reviews and Dissemination, consulting epidemiologists and 187 188 evidence-based medicine experts, with adaptations by methodologists and NHLBI staff. We assessed the certainty of evidence by using GRADE pro profiler⁵⁵ (GRADE working group, 189 190 McMaster University and Evidence Prime Inc) at the outcome level (e-Table 7). **Results** 191 **Study Characteristics** 192

A total of 17561 patients from 52 articles^{32-35,42-47,56-97} (Ivermectin n=7509, No
Ivermectin n= 10052) were included in the pooled analysis, 14019 patients from 44 studies

It is made available under a CC-BY-NC-ND 4.0 International license .

195	(Ivermectin n=3913, No Ivermectin n=10106) were included in quantitative synthesis (e-Table 1,
196	Figure 1). Out of 33 trials, 26 were true RCTs (e-Table 1, Figure 1). The remaining 19 studies
197	were observational and included 6 case-series (e-Table 1, Figure 1). Out of 52, 13 articles were
198	available as preprints, Huvemec trial ⁷⁶ details were obtained online and clinicaltrials.gov was
199	used for data extraction for 1 trial ⁶⁵ (e-Table 1, Figure 1). Due to absence of informed consent,
200	blinding and randomization, we considered Veerapaneni et al's ⁹³ study as case control study.
201	Primary Outcomes
202	(A) Mortality
203	Meta-analysis Overall
204	Total 29 studies reported mortality rate in patients receiving Ivermectin (279/3240) vs no-
205	Ivermectin therapy (1347/9407). The odds of mortality in the Ivermectin group were lower
206	compared to control group but the heterogeneity was high (OR 0.54, 95% CI 0.34-0.86, p=0.009;
207	I^2 =75%) (Figure 2A). Evidence was graded very low (e-table 7). In sensitivity analysis, we
208	observed similar mortality benefit with moderate heterogeneity after excluding study by Soto-
209	Becerra et al ⁹² (OR 0.49, 95% CI 0.32-0.75, p=0.001; I ² =52%) (Figure 2B).
210	Subgroup analysis by study design
211	Subgroup: Clinical trials
212	We performed subgroup analysis of 18 clinical trials (RCTs N=15, Non-RCTs N=3) and
213	observed similar mortality benefit (OR 0.47, 95% CI 0.25-0.90, p=0.02; I^2 =59%) (Figure 3A) but
214	evidence was graded low (e-table 7). On excluding Lima-Morales et al ⁴³ for sensitivity analysis,
215	benefit was observed with low heterogeneity but was not statistically significant (OR 0.61, 95%

216 CI 0.37-1.02, p=0.06; I²=19%) (e-Figure 1).

It is made available under a CC-BY-NC-ND 4.0 International license .

217 Subgroup: RCTs

We analyzed clinical severity-based data in 15 RCTs which included patients treated with 218 219 Ivermectin on inpatient or outpatient basis. In the mild/moderate subgroup, the odds of mortality 220 were lower with moderate heterogeneity but did not reach statistical significance (OR 0.31, 95%) CI 0.09-1.04, p=0.06; I^2 =45%) (Figure 3B). Similarly, mortality benefit was not statistically 221 significant in the severe/critical subgroup (OR 0.86, 95% CI 0.51-1.45, p=0. 56; $I^2=0\%$) (Figure 222 223 3C). Certainty of evidence was low in the mild/moderate and severe/critical subgroup (e-table 7). In sensitivity analysis, after excluding Vallejos et al⁹⁶ from the mild-moderate subgroup, 224 the odds of mortality decreased with low heterogeneity and reached statistical significance (OR 225 0.21, 95% CI 0.06-0.69, p=0.01; $I^2=24\%$) (e-Figure 2). Therefore, in mild/moderate COVID-19 226 227 patients, Ivermectin may possibly be useful for reducing mortality when we used as an adjuvant 228 therapy. 229 **Observational studies** Mortality benefit was not statistically significant in subgroup analysis of 11 observational 230 studies (OR 0.64, 95% CI 0.35-1.16, p=0.14; I^2 =73%) (Figure 3D) and evidence was graded very 231 low (e-table 7). After excluding Soto-Becerra et al⁹² in sensitivity analysis, we observed 232 233 statistically significant mortality benefit with moderate heterogeneity (OR 0.54, 95% CI 0.32-0.92, p=0.02; I²=38%) (e-Figure 3). 234

235 Subgroup analysis for hospitalized patients

236 Overall

In the subgroup analysis for hospitalized patients (studies N=18) mortality benefit was not statistically significant (OR 0.65, 95% CI 0.42-1.00, p=0.05; I^2 =66%) (Figure 3E). Evidence was very low (e-table 7). After excluding Soto-Becerra et al⁹² in sensitivity analysis, we

It is made available under a CC-BY-NC-ND 4.0 International license .

observed statistically significant lower odds of mortality with moderate heterogeneity (OR 0.58,

241 95% CI 0.39-0.87, p=0.008; I^2 =37%) (e-Figure 4).

242 Subgroup: Inpatient RCTs

243 We analyzed clinical severity-based data in 9 RCTs with only hospitalized patients. It

showed mortality benefit that was not statistically significant in the mild-moderate COVID-19

subgroup (OR 0.18, 95% CI 0.02-1.25, p=0.08; I^2 =61%) (Figure 3F) and in the severe/critical

246 COVID-19 subgroup (OR 0.86, 95% CI 0.51-1.45, p=0.56; $I^2=0\%$) (Figure 3G). Evidence was

graded low in both the subgroup analyses (e-table 7). After excluding Abd-elsalam et al^{94} in

sensitivity analysis for mild-moderate COVID-19, mortality benefit was statistically significant

249 (OR 0.06, 95% CI 0.01-0.33, p=0.001; $I^2 = 0\%$) (e-Figure 5).

250 Subgroup: Inpatient Observational studies

251 In the analysis of 8 observational studies with only hospitalized patients, significant

252 mortality benefit was not seen, and heterogeneity was high (OR 0.70, 95% CI 0.38-1.30, p=0.26;

253 $I^2=77\%$) (Figure 3H). Evidence was graded very low (e-table 7). In sensitivity analysis, after

excluding Soto-Becerra et al⁹² no significant mortality benefit was seen and heterogeneity was

255 moderate (OR 0.58, 95% CI 0.32-1.05, p=0.07; $I^2=50\%$) (e-Figure 6).

256 (B) Effect of Ivermectin monotherapy compared with Placebo/Standard of Care as per

257 Cochrane's criteria

258 We identified 7 RCTs where they investigated the effect of ivermectin monotherapy with or

259 without standard of care compared to placebo or standard of care. Overall, no significant

260 mortality benefit was observed (OR 0.75, 95% CI 0.35-1.63, p=0.47; $I^2=0\%$) (Figure 4). In

severity based subgroup analysis, the result remained same for mild/moderate subgroup (OR

262 0.71, 95% CI 0.27-1.87, p=0.49; I²=0%) and severe/critical subgroup (OR 0.83, 95% CI 0.23-

It is made available under a CC-BY-NC-ND 4.0 International license .

263 3.02, p=0.78; I^2 =NA) (Figure 4). Certainty of evidence was moderate overall and in the

264 mild/moderate subgroup, however it was graded low in severe/critical subgroup due to small

sample size (e-table 7).

266 Pooled Analysis for mortality

Pooled analysis of 37 studies out of 52 studies, yielded a rate of 3.6%, 95% CI 2.1-6.3;

268 $I^2 = 93.87\%$ (e-Figure 7).

269 (C) Need for ICU admission

270 Meta-analysis

In 5 studies (out of 52), 27/263 in the Ivermectin arm, 52/322 in the control arm needed

ICU admission. Benefit with Ivermectin was not statistically significant (OR 0.48, 95% CI 0.17-

273 1.37, p=0.17; l^2 =59%) (Figure 5A). Evidence was graded very low (e-table 7). In sensitivity

analysis, after excluding Galan et al^{71} we observed statistically significant benefit (OR 0.32, 95%)

275 CI 0.11-0.92, p=0.03; I²=27%) (Figure 5B). Based on low grading of evidence and observed

276 low-moderate heterogeneity in analysis, Ivermectin may be helpful in combination therapy in

277 decreasing need for ICU admission. Further validation with well-designed pragmatic platform

trials is needed.

279 **Pooled Analysis**

280 Pooled ICU admission rate obtained from 8 studies out of 52 studies was 5.4%, 95% CI 281 1.9-14.7; $I^2=91.9\%$ (e-Figure 8).

It is made available under a CC-BY-NC-ND 4.0 International license .

282 Secondary Outcomes

283 (A) Need for Mechanical Ventilation

- 284 Meta-analysis
- 285 Overall, 12 studies documented the need for mechanical ventilation. 71/1362 patients
- receiving Ivermectin and 88/1154 patients in the control arm required mechanical ventilation.
- 287 The benefit of Ivermectin was not statistically significant (OR=0.75, 95%CI 0.52-1.08, p=0.12;
- **288** $I^2=0\%$) (Figure 5C). Evidence was graded very low (e-table 7). On excluding Galan et al⁷¹ in
- sensitivity analysis, benefit observed was not statistically significant and showed no
- 290 heterogeneity (OR 0.68, 95% CI 0.45-1.01, p=0.06; $I^2=0\%$) (Figure 5D).

291 **Pooled Analysis**

- 292 The rate of need for mechanical ventilation based on 14 studies (out of 52 studies) was
- 293 3.9%, 95% CI 1.7-8.6; I²=87.2% (e-Figure 9).
- 294 (B) Adverse events

295 Meta-analysis

- A total of 22 studies reported data for rate of adverse-events in the Ivermectin-arm
- 297 (292/1405) vs control group (288/1372). We did not find an association between Ivermectin and
- rate of adverse events as compared to controls (OR 0.87, 95% CI 0.67-1.13, p=0.30; $I^2=1\%$).
- 299 (Figure 5E) but evidence was graded very low (e-table 7). In sensitivity analysis, after excluding
- 300 Veerapaneni et al⁹³ incidence of adverse effects with Ivermectin was similar to that of the control
- 301 group but was not conclusive (OR 0.84, 95% CI 0.65-1.08, p=0.18; $I^2=0\%$) (Figure 5F).

302 Pooled Analysis

303 A total of 38 studies (out of 52 studies) yielded a pooled rate of 6.6%, 95% CI 3.9-11.1; 304 I^2 =92.2% (e-Figure 10).

It is made available under a CC-BY-NC-ND 4.0 International license .

305 (C) Viral Clearance

Twenty-two studies reported data for patients achieving viral clearance: 1036/1327 in the 306 Ivermectin arm while 790/1206 patients in the non-Ivermectin arm tested negative for RT-PCR. 307 308 The analysis indicated that patients in the Ivermectin-arm showed higher odds of achieving viral 309 clearance when compared to the control group at a given point in time (OR 3.52,95% CI 1.81-6.86, p<0.01; I^2 =85%) (figure 6A). Evidence level was low (e-table 7). When we excluded 310 Mourva et al⁸⁵ in the sensitivity analysis, similar benefit was observed but heterogeneity 311 remained high (OR 2.79, 95% CI 1.52-5.10, p<0.01; I^2 =81%) (e-figure 11). 312 313 **(D)** Time to achieve Viral Clearance Eight studies presented data for the time needed for viral clearance in the Ivermectin 314 315 receiving arm vs that in the non-Ivermectin arm. The results show that the time needed to 316 achieve viral clearance was shorter by over 4 days in the Ivermectin group as compared to the 317 non-Ivermectin group, but with high heterogeneity (MD -4.12,95%CI -7.59,-0.65, p=0.02; 318 I^2 =98%) (figure 6B). Evidence level was low (e-table 7). In sensitivity analysis, benefit was seen but heterogeneity remained high after excluding Khan et al's study⁷⁷ (MD -3.24, 95%CI -5.37,-319 1.10, p=0.003; I²=92%) (e-figure 12). 320

321 (D) Need for hospitalization

Six studies described information for the number of patients requiring hospitalization when receiving Ivermectin (113/1074) as compared to those not receiving it (212/947). As per the analysis, Ivermectin group showed lower need for hospitalization as compared to controls but with high heterogeneity (OR 0.34, 95% CI 0.16-0.75, p=0.008; I^2 =78%) (Figure 6C). Evidence was low grade (e-table 7). On excluding Lima Morales et al⁴³ in sensitivity analysis, similar

It is made available under a CC-BY-NC-ND 4.0 International license .

benefit was seen with moderate heterogeneity but without statistical significance (OR 0.43, 95% CI 0.18-1.01, p=0.05; I^2 =59%) (e-figure 13).

329 (F) Length of hospital stay

330 We analyzed data from 9 studies regarding the duration of hospital stay in the Ivermectin 331 vs control arm. In this meta-analysis, we found that the benefit of Ivermectin in reducing the 332 duration of hospital stay was not statistically significant and heterogeneity was high (MD -1.80, 333 95% CI -3.69,0.08, p= 0.06; I^2 =94%) (Figure 6D). Evidence was low grade (e-table 7). In the sensitivity analysis, we excluded Khan et al's study⁷² and the duration of hospital stay was 334 shorter by one day in the Ivermectin arm compared to non-Ivermectin arm with high 335 heterogeneity and no statistical significance (MD -1.16, 95%CI -2.42, -0.1, p=0.07; I^2 =84%) (e-336 337 figure 14).

338 Discussion

Our meta-analysis suggests that the role of Ivermectin in improving patient survival in 339 340 COVID-19 is uncertain. However, Ivermectin might help more patients achieve viral clearance, 341 in a shorter duration of time and may also help reduce the need for hospitalization when used in combination therapy. Its benefit in reducing the need for admission to the ICU, mechanical 342 343 ventilation and the duration of hospital stay cannot be concluded with confidence. Its relation to 344 the incidence of adverse effects is inconclusive. Further, our pooled analysis indicates that 345 Ivermectin treatment may be linked to lower death rate and better clinical outcomes with a low incidence of adverse effects. The inherent methodological limitations and risk of bias conferred 346 variable evidence grading in the findings in various patient outcomes. 347

It is made available under a CC-BY-NC-ND 4.0 International license .

348 Mortality

349	Several systematic review and meta-analysis were performed to investigate the efficacy
350	of ivermectin for the treatment and prevention of COVID-19, with mixed results in meta-
351	analyses and conclusions. Meta-analyses done by Padhy et al 98 (studies N=3), Hill et al 99
352	(studies N=6) (retracted ¹⁰⁰), Lawrie et al ¹⁰¹ (studies N=5), Nardelli et al ¹⁰² (studies N=7), Kow
353	et al ¹⁰³ (studies N=6), Bryant et al ¹⁰⁴ (studies N=13), Kory et al ¹⁰⁵ (studies N=10), Hariyanto et
354	al^{106} (studies N=8) and the BIRD group ¹⁰⁷ (studies N=13) found Ivermectin to be conclusively
355	linked to lower mortality when compared to usual treatment. A network meta-analysis ¹⁰⁸ (studies
356	N=2) reported that Ivermectin was linked to lower mortality with a very close statistical
357	significance. Casteneda-Sabogal et al's meta-analysis ^{109} (studies N=6) and Roman et al ^{110}
358	(studies N=5) found no conclusive association of Ivermectin with reduced mortality. Of note, the
359	above three studies ¹⁰⁸⁻¹¹⁰ reported low or very low certainty of evidence. However, most of the
360	above analyses have included the retracted study by Elgazzar et al ⁴⁸ . Recently published
361	Cochrane's review ¹¹¹ of highly selected low-risk bias studies aimed at evaluating the true-effect
362	of Ivermectin in COVID-19. They expressed uncertainty regarding the effect of Ivermectin on
363	COVID-19 mortality based on 2 outpatient and 2 inpatient RCTs ¹¹¹ . Our sample size exceeds
364	(studies N=29) that of all the aforementioned studies. We observed mortality overall (N=29) and
365	in the clinical trials subgroup (N=18) meta-analysis. However, no mortality benefit was observed
366	in therapeutic RCTs (mild-moderate N=12, severe/critical N=6), inpatient RCTs (mild-moderate
367	N=5, severe/critical N=6) and observational studies (overall N=11, Inpatient N=8). Using the
368	selection criteria used in Cochrane's meta-analysis, we did not observe a mortality benefit when
369	we limit the analysis for Ivermectin monotherapy in comparison to standard of care or
370	placebo ¹¹¹ . We would like to emphasize the fact that the observed mortality benefit in some

It is made available under a CC-BY-NC-ND 4.0 International license .

371	analyses was frequently seen when Ivermectin was used in combination therapy especially with
372	vitamins, trace elements, other antimicrobials, and steroids. Beneficial effect of steroids has been
373	already been established, which was frequently used as part of standard of care ¹¹² . As we know
374	proper nutrition and activation of the immune system are two crucial elements in fighting the
375	COVID-19 infection ¹¹³ therefore it is possible that supplemental vitamins and minerals may help
376	in COVID-19 infection. However, clinical evidence does not currently support routine use of any
377	of these agents for the prevention or treatment of COVID-19, unless a patient has a confirmed or
378	suspected micronutrient deficiency ¹¹⁴ . We speculate that the observed mortality benefit of
379	Ivermectin was influenced by the use of these supplements, either through prescription or
380	patient's own decision for over the counter use.
381	Our pooled analysis resulting in a low mortality rate of 3.6% with use of Ivermectin.

Our pooled analysis resulting in a low mortality rate of 3.6% with use of Ivermectin, 381 mostly as an adjuvant therapy, is suggestive of its positive impact in lowering mortality in 382 383 COVID-19 patients. For a valid comparison, it is important to factor in the time window during 384 which the individual studies were conducted. Most studies recorded their data in the II&III 385 quarter of 2020 when mortality rates with various treatments were often higher in respective countries¹¹⁵. For instance, the mortality benefit with Ivermectin has been observed on a 386 magnified basis in a population study of 25 Peruvian states. The analysis of this mass 387 388 administration data revealed a 14 fold drop in deaths a couple months after starting of large-389 scale Ivermectin use and a 13 fold increase since limiting its use following change in Peru's political scenario¹¹⁶. 390

391 Need for ICU admission and Mechanical Ventilation

392 Due to the small number of studies and their small individual sample size, benefit with393 Ivermectin in reducing ICU admissions or mechanical ventilation cannot be concluded with

It is made available under a CC-BY-NC-ND 4.0 International license .

394	confidence. In our pooled analysis, we observed significantly lower rates for ICU admission
395	(5.4%) and mechanical ventilation (3.9%) in Ivermectin-treated patients, mostly as an adjuvant
396	therapy, when compared to other treatments ¹¹⁷⁻¹¹⁹ . It must be noted that our pooled analysis
397	mostly included mild/moderate patients, which may skew the results in favor of Ivermectin.
398	Adverse events
399	Our analysis for adverse events was inconclusive. We noticed that most adverse events
400	were non-serious: nausea, vomiting, abdominal pain, diarrhea, pruritus, lethargy, vertigo,
401	tingling, numbness, anxiety, mild hyperglycemia etc. Yet, very few patients reported serious
402	events like organizing pneumonia, hyponatremia, erosive esophagitis, infections/infestations.
403	Erosive esophagitis can be attributed to concomitant use of Doxycycline ¹²⁰ ; hyponatremia ⁸⁰ was
404	likely from SIADH-a rare COVID-19 complication ¹²¹ . Only Lopez-Medina et al ⁸¹ (Ivermectin
405	dose = 1500 ug/Kg over 5 days) and Mahmud et al ^{45,122} (Ivermectin dose = 12 mg twice daily for 5
406	days) reported drug discontinuation due to adverse-reactions. Given the non-serious nature of
407	most adverse-reactions, and a low pooled rate of 6.6% in comparison to other available
408	treatments ^{23,123,124} , we suggest that Ivermectin was generally well tolerated.
409	Viral Clearance and time to achieve Viral Clearance
410	We observed that patients who received Ivermectin in combination with other drugs were
411	far more likely to test negative for RT-PCR as compared to the control group. Hariyanto et al's
412	meta-analysis ¹⁰⁶ (N=9) supports our findings. Contrary to our results, Roman et al ¹¹⁰ (N=4) and
413	Cochrane's review ¹¹¹ found no such difference.
414	Similarly, when used in combination therapy, Ivermectin appeared to have significantly
415	shortened the time to achieve viral clearance when compared to the non-Ivermectin arm. This

416 finding was also observed in the analysis of Lawrie et al¹⁰¹ (N=2), Hariyanto et al¹⁰⁶ (N=6) and

It is made available under a CC-BY-NC-ND 4.0 International license .

the BIRD group¹⁰⁷ (N=4), however, Lawrie et al's¹⁰¹ results were not statistically significant. It
must be noted that these outcomes are subject to technical variations because of the different
laboratory parameters as well as the day at which viral clearance was measured.

420 Need for hospitalization and duration of hospital stay

421 Our analysis suggests that Ivermectin treatment may help reduce the need for

422 hospitalization. Another study by the BIRD group 107 (N=2) also found this association, yet their

423 analysis did not reach statistical significance.

430

In our analysis, we found trends of shorter duration of hospital stay but our results were not conclusive, hence more data is needed to confirm this finding. Three other studies^{101,106,107} also found similar benefit, only one¹⁰⁷ was not statistically significant. While Roman et al¹¹⁰ observed that Ivermectin was associated with a longer hospital stay; but without statistical significance. Recently, Cochrane's review¹¹¹ also did not find an association between Ivermectin and duration of hospitalization. We must acknowledge the high variation in clinical decision

making as well as the availability of resources with respect to hospitalization outcomes.

431 Our analysis for the true effect of Ivermectin is inconclusive, which supports the conclusion of Cochrane's review¹¹¹ that Ivermectin may or may not be effective by itself. 432 433 COVID-19, being a complex, multi-stage, and multi-system disease, requires a multi-pronged approach. Hazan et al⁹⁷ enumerated several microbial diseases currently being successfully 434 435 treated by a combination of multiple drugs with different individual mechanisms of actions. They highlighted another benefit of multidrug therapy: to avert cases of drug-resistance such as those 436 occurring with Ivermectin-monotherapy against parasitic infections. This is crucial since the 437 438 newly emerging SARS-CoV2 strains have perpetuated the pandemic in spite of desperate 439 measures taken world-wide. Also, this approach may address concerns regarding the adverse

It is made available under a CC-BY-NC-ND 4.0 International license .

effects associated with high dose of Ivermectin. Because, drug combinations can possibly boost
drug potency such as with the combination used by Hazan et al⁹⁷, thus rendering moderate doses
to be more effective. Therefore, it is imperative that we thoroughly explore Ivermectin as a part
of a multidrug regimen.

On the starting point of the COVID-19 disease spectrum is the acute infectious phase that 444 lasts for up to 2 weeks and is characterized by viral replication¹²⁵. This is followed by the hyper-445 inflammatory state marked by rise in inflammatory markers¹²⁵. Those surviving this phase may 446 experience long-term multi-organ sequelae for up to six months or even a year 126,127 . Patients 447 progressing to the severe stage require hospitalization and mortality rates among hospitalized 448 COVID-19 patients can be as high as 25%¹²⁸. Dwindling economies, overburdened healthcare 449 systems and the consequent dearth of resources further worsen the prognosis of hospitalized 450 451 patients, especially in low-income countries. Once progressed to the critical stage, mortality rate of around 50% has been recorded¹²⁹. The management of severe and critical patients mainly 452 consists of supportive treatment for complications of severe COVID-19¹³⁰. The available 453 454 evidence of the efficacy and safety of the recommended drugs for severe and critical COVID-19 patients is not promising¹³¹⁻¹³⁴. Even before the pandemic, much emphasis has been laid on the 455 importance of preventive and early treatment strategies for ARDS and sepsis to achieve a higher 456 survival rate in patients¹³⁵⁻¹³⁸. Drawing upon these recommendations, we hypothesize that 457 458 employing Ivermectin as an adjuvant therapy for early treatment of COVID-19 cases may allow the body to mount an adequate and well-regulated immune response, thus leading to better 459 460 outcomes. Considering the bleak prognosis of COVID-19 at the advanced stage, we postulate 461 that we may potentially improve patient outcomes by actively arresting its progression to severe 462 stages with effective and safe early adjuvant treatments like Ivermectin. Finally, we suggest that

It is made available under a CC-BY-NC-ND 4.0 International license .

463 understanding the course of this disease- both pathophysiological and symptomatic, and

464 leveraging it is key to achieving the best outcomes at both-patient and population level.

465 Strengths

466 To our knowledge, this is the largest patient sample size for a systematic review and meta-analysis on the use of Ivermectin for COVID-19. This study integrates data of 467 approximately 17,000 patients from 52 studies- both trials and observational, conducted globally. 468 469 Additionally, we obtained robust evidence by conducting various subgroup analyses. One noteworthy Ivermectin study, a large clinical trial⁴⁸, was recently withdrawn on grounds of 470 ethical misconduct. Its strongly positive findings accounted for significant effect size in the 471 472 meta-analyses published so far. This has led us to question the existing conclusions regarding the 473 efficacy of this drug. Ours would be the first meta-analysis that excluded the flawed study to clear the air regarding the effect of Ivermectin in COVID-19 for a stronger empirical evidence of 474 475 Ivermectin's efficacy. We also excluded studies which did not meet the rigor of true RCTs in the 'RCTs' subgroup. We used GRADE-pro tool⁵⁵ to rate certainty of evidence for all outcomes, 476 477 which was not done in past to provide more insight. The GRADE framework is known to be the most widely used assessment to rate quality of evidence⁵⁵. Sensitivity analyses were performed 478 479 with the aim of testing the robustness of results. Moreover, we performed pooled analyses to 480 incorporate data from uncontrolled studies.

481 Limitations

Our results are to be interpreted carefully bearing in mind that we included several nonpeer-reviewed articles to obtain the latest data. We cannot preclude the possibility of unreported biases and confounders that could have been recognized by a peer-review process. Furthermore, there was significant heterogeneity in treatment protocols used for dosage, duration, route of

It is made available under a CC-BY-NC-ND 4.0 International license .

486 administration in interventional and control group. Our analyses may not have accounted for 487 confounding by concomitant therapy. We only analyzed the mortality outcome as per Cochrane's 488 strict selection criteria for Ivermectin monotherapy compared to standard of care/placebo. Patient 489 demographics and outcome measures varied among different studies. Few studies documented 490 the inclusion of patients <18 years of age. However, the mean/median and dispersion values consistently suggested a predominantly adult population. The clinical classification for severity 491 492 was inconsistent across the included studies. Most studies were conducted on patients with mild 493 /moderate presentation, which limits the generalizability of our results.

494 Apart from this, there was insufficient data regarding the time of treatment in the course 495 of the disease, hence inferences could not be made in that regard. We could not confirm adequate 496 control-matching in some observational studies. We advise discretion in interpretation of our 497 results for adverse-event rate since most of the reported adverse-effects could not be measured 498 objectively by investigators. Because most of the studies were conducted in developing nations, 499 not everyone underwent RT-PCR testing owing to limited resources; clinical diagnosis was used 500 instead. Even though RT-PCR is the gold standard for diagnosis, it is subject to its limitations. By virtue of its design, we postulate that this meta-analysis formulated with a random-effects 501 502 model may have addressed some of the heterogeneity stemming from the above factors. Lastly, 503 we must acknowledge the subjective nature of the GRADE tool used to evaluate the level of evidence⁵⁵. 504

505 Current status of Ivermectin

In February 2021, the NIH declared that it neither recommends for or against using
Ivermectin for COVID-19¹³⁹ due to inadequate data. For further guidance, they require evidence
from larger, well-designed and well-executed trials. As of March 5,2021, the FDA has warned

It is made available under a CC-BY-NC-ND 4.0 International license .

509	people against using Ivermectin for COVID-19 ¹⁴⁰ , specifically against self-medicating with
510	veterinary Ivermectin formulations ^{140,141} . They are yet to review the evidence but have initiated a
511	preliminary research. In late March, the EMA (European Medicines Agency) stated that
512	Ivermectin cannot be recommended for the prevention or treatment of COVID-19 outside
513	clinical trials ¹⁴² . Similarly, the WHO suggested limiting Ivermectin use to clinical trials until
514	more data is available ¹⁴³ . A large phase 3 clinical trial evaluating the use of Ivermectin in
515	COVID-19 patients with mild to moderate symptoms is yet to be concluded ¹⁴⁴ . The NIH, FDA
516	,CDC, EMA and several other important government and private sector bodies will collaborate
517	on this "Master protocol" titled ACTIV-6 that focuses on rigorous testing of up to seven
518	repurposed drugs ¹⁴⁵ . Recently, the CDC issued warning against the use of non-prescription
519	Ivermectin as well as the ingestion of Ivermectin-containing topical or veterinary products and
520	advised seeking immediate medical care for any adverse effects arising out of such events ¹⁴⁶ .
521	Conclusion

522 In summary, based on updated evidence, benefit of Ivermectin as monotherapy or in 523 combination treatment for lowering the COVID-19 associated mortality is inconclusive due to 524 lack of high-quality RCTs. Ivermectin combination therapy may play a role in controlling the viral replication and preventing the need for hospitalization. Using well-designed larger 525 observational studies^{147,148} and clinical trials, we need to further investigate its efficacy, its ideal 526 527 dosage and timing in the disease course, drug interactions and possible synergistic drug 528 combinations to achieve maximum benefit. We also need to evaluate the benefit of Ivermectin 529 for treating the various emerging strains as well as its role in vaccinated individuals. We propose pragmatic practice embedded platform trials¹⁴⁹ to test this and other re-purposed and novel 530 therapies specifically in severe COVID-19 patients and other critically ill patients. We 531

- 532 recommend the medical practitioners to exercise caution until further evidence is available and
- 533 use their best clinical judgement while prescribing Ivermectin in COVID-19 patients.

It is made available under a CC-BY-NC-ND 4.0 International license .

534 **References:**

Cucinotta D. Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 535 1. 536 2020:91(1):157-160. 537 2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in 538 real time. Lancet Infect Dis. 2020;20(5):533-534. 539 Domecg JP, Lal A, Sheldrick CR, et al. Outcomes of Patients With Coronavirus Disease 3. 540 2019 Receiving Organ Support Therapies: The International Viral Infection and 541 Respiratory Illness Universal Study Registry. Critical Care Medicine. 9000;Online First. Bansal V, Singh R, Bhurwal A, Rathore S, Kashyap R. 117: Obesity Is a Risk Factor for 542 4. 543 Increased COVID-19 Severity: A Systemic Review and Meta-Regression. Critical Care 544 Medicine.49(1):43. 545 5. Menon T. Gandhi SAQ. Tarig W. et al. Impact of Chronic Kidney Disease on Severity and Mortality in COVID-19 Patients: A Systematic Review and Meta-analysis. Cureus. 546 547 2021;13(4):e14279. Menon T, Sharma R, Kataria S, et al. The Association of Acute Kidney Injury With 548 6. 549 Disease Severity and Mortality in COVID-19: A Systematic Review and Meta-Analysis. 550 Cureus. 2021;13(3):e13894. Singh R, Shiza ST, Saadat R, Dawe M, Rehman U. Association of Guillain-Barre 551 7. 552 Syndrome With COVID-19: A Case Report and Literature Review. Cureus. 553 2021;13(3):e13828. 554 8. Menon T, Sharma R, Earthineni G, et al. Association of Gastrointestinal System With 555 Severity and Mortality of COVID-19: A Systematic Review and Meta-Analysis. Cureus. 556 2021;13(2):e13317. 557 9. Razonable RR, Pennington KM, Meehan AM, et al. A Collaborative Multidisciplinary 558 Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. 559 Mayo Clinic Proceedings. 2020;95(7):1467-1481. 560 10. Rathore SS, Rojas GA, Sondhi M, et al. Myocarditis associated with Covid-19 disease: a 561 systematic review of published Case reports and Case series. Preprints; 2021/02/01/ 562 2021. 563 11. Sheraton M, Deo N, Kashyap R, Surani S. A Review of Neurological Complications of 564 COVID-19. Cureus. 2020;12(5):e8192. 565 12. Khan H, Sabzposh H, Deshpande S, Kashyap R. Pregnancy during COVID-19 566 pandemic - Maternal and neonatal outcomes: A concise review. International Journal of 567 Academic Medicine. 2020;6(4):287-293. 568 Shah K, Mann S, Singh R, Bangar R, Kulkarni R. Impact of COVID-19 on the Mental 13. 569 Health of Children and Adolescents. Cureus. 2020;12(8):e10051. Sheraton M, Deo N, Dutt T, Surani S, Hall-Flavin D, Kashyap R. Psychological effects of 570 14. 571 the COVID 19 pandemic on healthcare workers globally: A systematic review. Psychiatry 572 Res. 2020;292:113360. 573 Singh R, Kashyap R, Hutton A, Sharma M, Surani S. A Review of Cardiac Complications 15. 574 in Coronavirus Disease 2019. Cureus. 2020;12(5):e8034. 575 Bhalala U. Gist K. Tripathi S. et al. 145: Pediatric COVID-19: A Report From Viral 16. 576 Infection and Respiratory Illness Universal Study (VIRUS). Critical Care 577 Medicine.49(1):58. 578 17. Tripathi S, Gist K, Chiotos K, et al. 61: Risk Factors for Severe COVID-19 Illness in 579 Children: Analysis of the VIRUS: COVID-19 Registry. Critical Care Medicine.49(1):32. 580 18. Md Insiat Islam R. Current Drugs with Potential for Treatment of COVID-19: A Literature 581 Review. J Pharm Pharm Sci. 2020;23(1):58-64.

582 583	19.	Gilzad-Kohan H, Jamali F. Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-
584		Converting Enzyme-2. J Pharm Pharm Sci. 2020;23:259-277.
585	20.	Bansal V, Mahapure KS, Mehra I, et al. Mortality Benefit of Convalescent Plasma in
586	20.	COVID-19: A Systematic Review and Meta-Analysis. <i>Front Med (Lausanne).</i>
587		2021;8:624924.
588	21.	Singh R, Rathore SS, Khan H, et al. Mortality and Severity in COVID-19 Patients on
589		ACEIs & ARBs-A Meta-Regression Analysis. <i>medRxiv</i> . 2021.
590	22.	Mahmud S, Nagraj S, Karia R, et al. 140: Efficacy and Safety of Tocilizumab in
591		Hospitalized COVID-19 Patients: A Systematic Review. Critical Care Medicine.
592		2021;49(1):55.
593	23.	Bansal V, Mahapure KS, Bhurwal A, et al. Mortality Benefit of Remdesivir in COVID-19:
594		A Systematic Review and Meta-Analysis. Front Med (Lausanne). 2020;7:606429.
595	24.	Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and
596		exceed expectations. J Antibiot (Tokyo). 2017;70(5):495-505.
597	25.	Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against
598		SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020;19(1):23.
599	26.	Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid
600		protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis
601		Virus replication. Antiviral Res. 2013;100(3):662-672.
602	27.	Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4
603		non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor
604		Ivermectin. Antiviral Res. 2013;99(3):301-306.
605	28.	Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific
606		inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-
607		1 and dengue virus. <i>Biochem J.</i> 2012;443(3):851-856.
608	29.	DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful anti-
609		inflammatory agent for late-stage COVID-19. Open Heart. 2020;7(2).
610	30.	Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory
611		cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57(11):524-
612		529.
613	31.	Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug
614		ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res.
615	00	2020;178:104787.
616	32.	Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-on
617	00	Therapy in COVID-19 Management (Pilot Trial). <i>medRxiv</i> . 2020.
618	33.	Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin Is
619 620		Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease
620 621	0.4	2019: The Ivermectin in COVID Nineteen Study. <i>Chest.</i> 2021;159(1):85-92.
621	34.	Bhattacharya R, Ray I, Mukherjee R, Chowdhury S, Kulasreshtha M, Ghosh R.
622 622		Observational Study on Clinical Features, Treatment and Outcome of Covid 19 in a
623 624		Tertiary Care Centre in India - a Retrospective Case Series. International Journal of
625	25	Scientific Research. 2020;9(10):1-3.
625 626	35.	Chowdhury AMM, Shahbaz M, Karim MR, Islam J, Dan G, He SX. A Comparative Study on Ivermectin-Doxycycline and Hydroxychloroquine-Azithromycin Therapy on COVID-19
620 627		Patients. Eurasian Journal of Medicine and Oncology. 2021;5(1):63-70.
628	36.	Mega ER. Latin America's embrace of an unproven COVID treatment is hindering drug
629	50.	trials. <i>Nature</i> . 2020;586(7830):481-482.
630	37.	Trial Site Staff. Beyond The Roundup First EU Nation To Approve Ivermectin For
631	01.	Covid-19. <u>https://trialsitenews.com/beyond-the-roundup-first-eu-nation-to-approve-</u>
632		ivermectin-for-covid-19/. Published January 30, 2021. Accessed 02.14.2021.

633	38.	Nayar S, Khanna P, Anand P, et al. Ivermectin in Covid-19: Review of the Current
634		Evidence. The Indian Practitioner. 2021;74(3):27-33.
635	39.	AIIMS/ ICMR-COVID-19 National Task Force/Joint Monitoring Group (Dte.GHS).
636		CLINICAL GUIDANCE FOR MANAGEMENT OF ADULT COVID-19 PATIENTS. Ministry
637		of Health & Family Welfare, Government of India.
638		https://www.mohfw.gov.in/pdf/COVID19ManagementAlgorithm22042021v1.pdf.
639		Published 2021. Updated 04/22/2021. Accessed 04/25/2021.
640	40.	Chamie-Quintero JJ, Hibberd J, Scheim D. Sharp reductions in COVID-19 case fatalities
641		and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin
642		treatments. State-By-State, with Ivermectin Treatments (January 12, 2021). 2021.
643	41.	Yagisawa M, Foster PJ, Hanaki H, Ōmura S. Global trends in clinical studies of
644		ivermectin in COVID-19. THE JAPANESE JOURNAL OF ANTIBIOTICS. 2021;74:1.
645	42.	Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 Therapy with
646		Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient
647		Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated
648		Patients. medRxiv. 2020.
649	43.	Lima-Morales R, Mendez-Hernandez P, Flores YN, et al. Effectiveness of a multidrug
650		therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to
651		prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala,
652		Mexico. Int J Infect Dis. 2021;105:598-605.
653	44.	Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an adjunct treatment for hospitalized
654		adult COVID-19 patients: A randomized multi-center clinical trial. Research Square.
655		2020.
656	45.	Mahmud R, Rahman MM, Alam I, et al. Ivermectin in combination with doxycycline for
657		treating COVID-19 symptoms: a randomized trial. J Int Med Res.
658		2021;49(5):3000605211013550.
659	46.	Ravindra G, Chitra L, Madhur M, et al. Retrospective Assessment of Treatments of
660		Hospitalized Covid-19 Patients. medRxiv. 2021.
661	47.	Samaha AA, Mouawia H, Fawaz M, et al. Effects of a Single Dose of Ivermectin on Viral
662		and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical
663		Trial in Lebanon. <i>Viruses.</i> 2021;13(6).
664	48.	Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and Safety
665		of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic. Research Square.
666		2020.
667	49.	The Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version
668		5.4 for Windows. Oxford, England: The Cochrane Collaboration.
669		https://training.cochrane.org/online-learning/core-software-cochrane-
670		reviews/revman/revman-5-download. Published 2020. Accessed 01/31/2021.
671	50.	Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-Analysis Version
672		3. Biostat, Englewood, NJ 2013. <u>https://www.meta-</u>
673		analysis.com/index.php?cart=BBFA4702757. Published 2013. Accessed 01/31/2021.
674	51.	Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of
675		interventions. John Wiley & Sons; 2019.
676	52.	Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for
677	50	assessing risk of bias in randomised trials. <i>BMJ</i> . 2011;343:d5928.
678	53.	Balk EM, Bonis PA, Moskowitz H, et al. Correlation of quality measures with estimates of
679		treatment effect in meta-analyses of randomized controlled trials. <i>Jama</i> .
680	F 4	2002;287(22):2973-2982.
681	54.	National Heart L, and Blood Institute,. Development and Use of Study Quality
682		Assessment Tools. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-
683		tools, Updated 04/14/2021, Accessed 04/14/2021, 2020,

683 tools. Updated 04/14/2021. Accessed 04/14/2021, 2020.

684 685 686	55.	Schünemann H, Brożek J, Guyatt G, Oxman A. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. <i>Updated October.</i> 2013;2013.
687 688 689	56.	Afsar N, Ghauri MI, Abbas M, Mukarram MS, Peracha MY, Ishaq K. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting. <i>Available at SSRN 3734478.</i> 2020.
690 691	57.	Ahmed S, Karim MM, Ross AG, et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. <i>Int J Infect Dis.</i> 2021;103(Feb):214-216.
692 693 694	58.	Ahsan T, Rani B, Siddiqui R, et al. Clinical Variants, Characteristics, and Outcomes Among COVID-19 Patients: A Case Series Analysis at a Tertiary Care Hospital in Karachi, Pakistan. <i>Cureus</i> . 2021;13(4):e14761.
695 696	59.	Robin RC, Alam RF, Saber S, Bhiuyan E, Murshed R, Alam MT. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline.
697 698 699 700	60.	<i>Journal of Bangladesh College of Physicians and Surgeons.</i> 2020;38(0):10-15. Babalola OE, Bode CO, Ajayi AA, et al. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos. <i>QJM.</i> 2021.
701 702 703	61.	Biber A, Mandelboim M, Harmelin G, et al. Favorable outcome on viral load and culture viability using lvermectin in early treatment of non-hospitalized patients with mild COVID- 19, A double-blind, randomized placebo-controlled trial. <i>medRxiv</i> . 2021.
704 705 706	62.	Budhiraja S, Soni A, Jha V, et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience. <i>medRxiv.</i> 2020.
707 708	63.	Shah Bukhari KH, Asghar A, Perveen N, et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease. <i>medRxiv</i> . 2021.
709 710	64.	Camprubi D, Almuedo-Riera A, Marti-Soler H, et al. Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients. <i>PLoS One.</i> 2020;15(11):e0242184.
711 712	65.	Carvallo H. Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 - Study Results - ClinicalTrials.gov.
713 714		https://clinicaltrials.gov/ct2/show/results/NCT04425863?view=results. Published 2020. Updated 10/19/2020. Accessed 02/12/2021.
715 716 717 718	66.	Chaccour C, Casellas A, Blanco-Di Matteo A, et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. <i>EClinicalMedicine</i> . 2021;32(100720):100720.
719 720 721	67.	Zeeshan Khan Chachar A, Ahmad Khan K, Asif M, Tanveer K, Khaqan A, Basri R. Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients. <i>International Journal of Sciences</i> . 2020;9(09):31-35.
722 723 724	68.	Chahla RE, Ruiz LM, Mena T, et al. Cluster Randomised Trials-Ivermectin Repurposing For COVID-19 Treatment Of Outpatients With Mild Disease In Primary Health Care Centers. <i>Research Square.</i> 2021.
725 726 727	69.	Elalfy H, Besheer T, El-Mesery A, et al. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. <i>J Med Virol.</i> 2021;93(5):3176-3183.
728 729 730	70.	Espitia-Hernandez G, Munguia L, Diaz-Chiguer D, López-Elizalde R, Jimenez-Ponce F. Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study. <i>Biomedical Research</i> . 2020;31(5):129-133.
730 731 732 733	71.	Galan LEB, Santos NMD, Asato MS, et al. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. <i>Pathog Glob Health.</i> 2021;115(4):235-242.

734	72.	Gonzalez JLB, González Gámez M, Enciso EAM, et al. Efficacy and safety of Ivermectin
735		and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled
736		trial. <i>medRxiv</i> . 2021.
737	73.	Guzmán MJM, Castillo-Gonzalez A, Gonzalez JLB, et al. Factors associated with
738		increased mortality in critically ill COVID-19 patients in a Mexican public hospital: the
739		other faces of health system oversaturation. <i>medRxiv</i> . 2021.
740	74.	Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS. Controlled
741		randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19
742	75	patients in Baghdad, Iraq. <i>medRxiv</i> . 2020:2020.2010.2026.20219345.
743	75.	Hussain SMA, Shuayb M, Rahman M. Outcome of ivermectin and doxycycline in cancer
744 745		patients with COVID-19: A positive experience in Bangladesh. International Journal of
745 746	76.	Molecular & Immuno Oncology. 2021;6(1):27-29. Release HP. Kovid-19 - Huvemek® Phase 2 clinical trial Huvepharma
740 747	70.	https://huvemec.bg/covid-19-huvemec-klinichno-izpitanie/za-isledvaneto/. Updated
748		03/25/2021. Accessed 05/22/2021.
748	77.	Khan MSI, Khan MSI, Debnath CR, et al. Ivermectin Treatment May Improve the
750		Prognosis of Patients With COVID-19. Arch Bronconeumol (Engl Ed). 2020;56(12):828-
751		830.
752	78.	Ravikirti, Roy R, Pattadar C, et al. Ivermectin as a potential treatment for mild to
753	70.	moderate COVID-19 – A double blind randomized placebo-controlled trial. <i>medRxiv</i> .
754		2021.
755	79.	Kishoria N, Mathur SL, Parmar V, et al. IVERMECTIN AS ADJUVANT TO
756		HYDROXYCHOLOROQUINE IN PATIENTS RESISTANT TO STANDARD
757		TREATMENT FOR SARS-CoV-2: RESULTS OF AN OPEN-LABEL RANDOMIZED
758		CLINICAL STUDY. Paripex Indian Journal of Research. 2020;9(8):1-4.
759	80.	Krolewiecki A, Lifschitz A, Moragas M, et al. Antiviral effect of high-dose ivermectin in
760		adults with COVID-19: A proof-of-concept randomized trial. EClinicalMedicine. 2021;37.
761	81.	Lopez-Medina E, Lopez P, Hurtado IC, et al. Effect of Ivermectin on Time to Resolution
762		of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. Jama.
763		2021;325(14):1426-1435.
764	82.	Pierre L, Christine F. Ivermectin and COVID-19 in Care Home: Case Report. Journal of
765		Infectious Diseases and Epidemiology. 2021;7(4):1-4.
766	83.	Mohan A, Tiwari P, Suri T, et al. Ivermectin in mild and moderate COVID-19 (RIVET-
767	0.4	COV): a randomized, placebo-controlled trial. Research Square. 2021.
768	84.	Morgenstern J, Redondo JN, De León A, et al. The use of compassionate lvermectin in
769		the management of symptomatic outpatients and hospitalized patients with clinical
770		diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta
771		Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020. <i>J Clin Trials.</i>
772 773	85.	2020;11(S9:1000002):1-4. Mourya S, Thakur AS, Hada DS, Kulshreshtha VS, Sharma Y. Comparative Analytical
774	65.	Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in
775		Index Medical College Hospital and Research Center, Indore, India. International Journal
776		of Health and Clinical Research. 2021;4(6):265-267.
777	86.	Núñez AC, Yuca GG, Cervantes JML, Murcia APR, Juárez MAO, Martínez JJ.
778	00.	Therapeutic Efficacy of Ivermectin as an Adjuvant in the Treatment of Patients with
779		COVID-19 Study conducted at the Social Security Institute for Workers of the State of
780		Chiapas, ISSTECH, Mexico. International Journal of Innovative Science and Research
781		Technology. 2020;5(7):211-215.
782	87.	Podder CS, Chowdhury N, Sina MI, Haque WMMU. Outcome of ivermectin treated mild
783		to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study.
784		IMC Journal of Medical Science. 2020;14(2:002):11-18.

785	88.	Okumus N, Demirturk N, Cetinkaya RA, et al. Evaluation of the effectiveness and safety
786		of adding ivermectin to treatment in severe COVID-19 patients. BMC Infect Dis.
787 700	00	2021;21(1):411.
788 780	89.	Pott-Junior H, Bastos Paoliello MM, Miguel AQC, et al. Use of ivermectin in the
789 700	00	treatment of Covid-19: A pilot trial. <i>Toxicol Rep.</i> 2021;8(0):505-510.
790 791	90.	Rahman MA, Iqbal SA, Islam MA, Niaz MK, Hussain T, Siddiquee TH. Comparison of
791 792		viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. <i>Journal of Bangladesh College of Physicians and</i>
792 793		Surgeons. 2020;38:5-9.
793 794	91.	Shahbaznejad L, Davoudi A, Eslami G, et al. Effects of Ivermectin in Patients With
794 795	91.	COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial. <i>Clin Ther.</i>
796		2021.
797	92.	Soto-Becerra P, Culquichicón C, Hurtado-Roca Y, Araujo-Castillo RV. Real-world
798	52.	effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized
799		COVID-19 patients: results of a target trial emulation using observational data from a
800		nationwide healthcare system in Peru. <i>medRxiv.</i> 2020.
801	93.	Spoorthi V, Sasank S. Utility of ivermectin and doxycycline combination for the treatment
802		of SARS-CoV2. IAIM. 2020;7(10):177-182.
803	94.	Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of
804		ivermectin in COVID-19 treatment: A randomized controlled study. <i>J Med Virol.</i>
805	<u>-</u>	2021;93(10):5833-5838.
806	95.	Aref ZF, Bazeed S, Hassan MH, et al. Clinical, Biochemical and Molecular Evaluations
807		of Ivermectin Mucoadhesive Nanosuspension Nasal Spray in Reducing Upper
808	00	Respiratory Symptoms of Mild COVID-19. Int J Nanomedicine. 2021;16:4063-4072.
809	96.	Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients
810 811		with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. <i>BMC Infect Dis.</i> 2021;21(1):635.
812	97.	Hazan S, Dave S, Gunaratne AW, et al. Effectiveness of Ivermectin-Based Multidrug
813	97.	Therapy in Severe Hypoxic Ambulatory COVID-19 Patients. <i>medRxiv</i> . 2021.
814	98.	Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add
815	50.	on treatment in COVID 19: A systematic review and meta-analysis. <i>J Pharm Pharm Sci.</i>
816		2020;23:462-469.
817	99.	Hill A, Abdulamir A, Ahmed S, et al. Meta-analysis of randomized trials of ivermectin to
818		treat SARS-CoV-2 infection. Research Square. 2021.
819	100.	Hill A, Garratt A, Levi J, et al. Erratum: Expression of Concern: "Meta-analysis of
820		Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection". Open Forum Infect
821		Dis. 2021;8(8):ofab394.
822	101.	Lawrie T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-
823		analysis in support of the recommendation of the Front Line COVID-19 Critical Care
824		Alliance. (Latest version v1.2 - 6 Jan 2021). 2021.
825	102.	Nardelli P, Zangrillo A, Sanchini G, et al. Crying wolf in time of Corona: the strange case
826		of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-
827		saving treatment from clinical use? Signa Vitae. 2021;1:2.
828	103.	Kow CS, Merchant HA, Mustafa ZU, Hasan SS. The association between the use of
829		ivermectin and mortality in patients with COVID-19: a meta-analysis. Pharmacol Rep.
830		2021:1-7.
831	104.	Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of
832		COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis
833		to Inform Clinical Guidelines. Am J Ther. 2021.

834 835	105.	Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.
836	400	American Journal of Therapeutics. 2021;28(3):e299-e318.
837 838	106.	Hariyanto TI, Halim DA, Rosalind J, Gunawan C, Kurniawan A. Ivermectin and outcomes from Covid-19 pneumonia: A systematic review and meta-analysis of randomized clinical
839		trial studies. <i>Reviews in Medical Virology.</i> 2021;e2265:1-15.
840	107.	British Ivermectin Recommendation Development. The BIRD Recommendation on the
841		Use of Ivermectin for Covid-19. <u>https://www.francesoir.fr/sites/francesoir/files/media-</u>
842 843	108.	icons/bird-proceedings-02-03-2021-v151.pdf. Published 2021. Accessed 04.01.2021. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of
843 844	100.	pharmacological interventions for the treatment of COVID-19: A systematic review and
845		network meta-analysis. <i>PLoS Med.</i> 2020;17(12):e1003501.
846	109.	Castañeda-Sabogal A, Chambergo-Michilot D, Toro-Huamanchumo CJ, Silva-Rengifo
847		C, Gonzales-Zamora J, Barboza JJ. Outcomes of Ivermectin in the treatment of COVID-
848		19: a systematic review and meta-analysis. <i>medRxiv</i> . 2021:2021.2001.2026.21250420.
849 850	110.	Roman YM, Burela PA, Pasupuleti V, Piscoya A, Vidal JE, Hernandez AV. Ivermectin for
850 851		the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>medRxiv</i> . 2021.
852	111.	Popp M, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating
853		COVID-19. Cochrane Database Syst Rev. 2021;7(7):CD015017.
854	112.	NIH. Corticosteroids COVID-19 Treatment Guidelines.
855		https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticoster
856	110	oids/. Published 2021. Updated 08/04/2021. Accessed 08/25/2021.
857 858	113.	Derbyshire E, Delange J. COVID-19: is there a role for immunonutrition, particularly in the over 65s? <i>BMJ Nutr Prev Health.</i> 2020;3(1):100-105.
859	114.	Bauer SR, Kapoor A, Rath M, Thomas SA. What is the role of supplementation with
860		ascorbic acid, zinc, vitamin D, or N-acetylcysteine for prevention or treatment of COVID-
861		19? Cleve Clin J Med. 2020.
862	115.	World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. WHO.
863	110	https://covid19.who.int/. Updated 02.14.2021. Accessed 02.14.2021.
864 865	116.	Chamie-Quintero J, Hibberd JA, Scheim D. Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=. 002 for effect by state, then 13-fold increase
866		after ivermectin use restricted. 2021.
867	117.	Abate SM, Ahmed Ali S, Mantfardo B, Basu B. Rate of Intensive Care Unit admission
868		and outcomes among patients with coronavirus: A systematic review and Meta-analysis.
869		PLoS One. 2020;15(7):e0235653.
870	118.	Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY. Variation in outcome
871 872		of invasive mechanical ventilation between different countries for patients with severe COVID-19: a systematic review and meta-analysis. 2020.
872	119.	Richardson S. Presenting characteristics, comorbidities, and outcomes among 5700
874	110.	patients hospitalized with COVID-19 in the New York City area (published online ahead
875		of print, 2020 Apr 22). Jama.
876	120.	Jaspersen D. Drug-induced oesophageal disorders: pathogenesis, incidence, prevention
877	46.4	and management. Drug Saf. 2000;22(3):237-249.
878 870	121.	Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a
879 880	122.	clue in the times of pandemic! <i>Am J Physiol Endocrinol Metab.</i> 2020;318(6):E882-E885. Mahmud R. Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed
881	122.	Covid-19 Infection. Dhaka Medical College Bangladesh.
882		https://clinicaltrials.gov/ct2/show/study/NCT04523831. Published 2020. Updated
883		October 9, 2020. Accessed 02.14.2021.

884	123.	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -
885	123.	Final Report. N Engl J Med. 2020;383(19):1813-1826.
886	124.	Group WHOREAfC-TW, Sterne JAC, Murthy S, et al. Association Between
887	127.	Administration of Systemic Corticosteroids and Mortality Among Critically III Patients
888		With COVID-19: A Meta-analysis. <i>Jama</i> . 2020;324(13):1330-1341.
889	125.	Datta SD, Talwar A, Lee JT. A Proposed Framework and Timeline of the Spectrum of
890	120.	Disease Due to SARS-CoV-2 Infection: Illness Beyond Acute Infection and Public Health
891		Implications. Jama. 2020;324(22):2251-2252.
892	126.	Boscolo-Rizzo P, Guida F, Polesel J, et al. Sequelae in adults at 12 months after mild-to-
893	120.	moderate coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol. 2021.
894	127.	Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med.
895		2021;27(4):601-615.
896	128.	Gunster C, Busse R, Spoden M, et al. 6-month mortality and readmissions of
897	-	hospitalized COVID-19 patients: A nationwide cohort study of 8,679 patients in
898		Germany. PLoS One. 2021;16(8):e0255427.
899	129.	Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
900		Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases
901		From the Chinese Center for Disease Control and Prevention. Jama.
902		2020;323(13):1239-1242.
903	130.	CDC. Interim clinical guidance for management of patients with confirmed coronavirus
904		disease (COVID-19). Centers for Disease Control Prevention.
905		https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-
906		patients.html. Published 2020. Updated 02/12/2021. Accessed 06/19/2021.
907	131.	Group RC. Convalescent plasma in patients admitted to hospital with COVID-19
908		(RECOVERY): a randomised controlled, open-label, platform trial. Lancet.
909		2021;397(10289):2049-2059.
910	132.	Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment
911		With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-
912		analysis. <i>Jama.</i> 2021;325(12):1185-1195.
913	133.	Garibaldi BT, Wang K, Robinson ML, et al. Comparison of Time to Clinical Improvement
914 015		With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA
915	404	Netw Open. 2021;4(3):e213071.
916 017	134.	Bayram N, Ozsaygili C, Sav H, et al. Susceptibility of severe COVID-19 patients to rhino-
917 019		orbital mucormycosis fungal infection in different clinical manifestations. <i>Jpn J</i>
918 010	125	Ophthalmol. 2021;65(4):515-525.
919 920	135.	Festic E, Kor DJ, Gajic O. Prevention of acute respiratory distress syndrome. <i>Curr Opin Crit Care</i> . 2015;21(1):82-90.
920 921	136.	Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung
922 922	150.	injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J
923		Respir Crit Care Med. 2011;183(4):462-470.
924	137.	Lat I, Coopersmith CM, De Backer D, et al. The Surviving Sepsis Campaign: Fluid
925	107.	Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients. Crit Care
926		Med. 2021;49(4):623-635.
927	138.	Youkee D, Hulme W, Roberts T, Daniels R, Nutbeam T, Keep J. Time Matters: Antibiotic
928		Timing in Sepsis and Septic Shock. <i>Crit Care Med.</i> 2016;44(10):e1016-1017.
929	139.	National Institutes of Health. Ivermectin COVID-19 Treatment Guidelines. National
930		Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/antiviral-
931		therapy/ivermectin/. Published 2020. Updated February 11, 2021. Accessed 02.14.2021.
932	140.	FDA. FAQ: COVID-19 and Ivermectin Intended for Animals FDA. FDA.
933		https://www.fda.gov/animal-veterinary/product-safety-information/faq-covid-19-and-


 935 02.14.2021. 936 141. FDA. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19 FDA. https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin- treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021. 939 142. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials European Medicines Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin- prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. Updated 03.22.2021. Accessed 04.10.2021. 944 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who- advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021. 948 144. ACTIV-6: COVID-19 Study of Repurposed Medications. https://clinicaltrials.gov/ct2/show/NCT04885530. Published 2021. Updated 08/30/2021.
 https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin- treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021. 142. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials European Medicines Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin- prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. Updated 03.22.2021. Accessed 04.10.2021. 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who- advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021. 144. ACTIV-6: COVID-19 Study of Repurposed Medications.
 938 treat-or-prevent-covid-19. Published 2021. Updated 03.05.2021. Accessed 04.10.2021. 939 142. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials European Medicines 941 Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin- prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. 943 Updated 03.22.2021. Accessed 04.10.2021. 944 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who- advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021. 948 144. ACTIV-6: COVID-19 Study of Repurposed Medications.
 939 142. European Medicines Agency. EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomised clinical trials European Medicines Agency. <u>https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-</u> <i>prevention-treatment-covid-19-outside-randomised-clinical-trials</i>. Published 2021. 943 Updated 03.22.2021. Accessed 04.10.2021. 944 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 19 within clinical trials. <u>https://www.who.int/news-room/feature-stories/detail/who-</u> advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021. 948 144. ACTIV-6: COVID-19 Study of Repurposed Medications.
 940 or treatment of COVID-19 outside randomised clinical trials European Medicines 941 Agency. <u>https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-</u> 942 prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. 943 Updated 03.22.2021. Accessed 04.10.2021. 944 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 945 19 within clinical trials. <u>https://www.who.int/news-room/feature-stories/detail/who-</u> 946 advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 947 2021. Updated 03/31/2021. Accessed 08/25/2021. 948 144. ACTIV-6: COVID-19 Study of Repurposed Medications.
941Agency. https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials . Published 2021.943Updated 03.22.2021. Accessed 04.10.2021.944143.944143.94519 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who- 946advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials9472021. Updated 03/31/2021. Accessed 08/25/2021.948144.ACTIV-6: COVID-19 Study of Repurposed Medications.
 942 prevention-treatment-covid-19-outside-randomised-clinical-trials. Published 2021. 943 Updated 03.22.2021. Accessed 04.10.2021. 944 143. World Health Organization. WHO advises that ivermectin only be used to treat COVID- 945 19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who- 946 advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 947 2021. Updated 03/31/2021. Accessed 08/25/2021. 948 144. ACTIV-6: COVID-19 Study of Repurposed Medications.
943Updated 03.22.2021. Accessed 04.10.2021.944143.World Health Organization. WHO advises that ivermectin only be used to treat COVID-94519 within clinical trials. <a a="" detail="" feature-stories="" href="https://www.who.int/news-room/feature-stories/detail/who-946advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published9472021. Updated 03/31/2021. Accessed 08/25/2021.948144.ACTIV-6: COVID-19 Study of Repurposed Medications.</td></tr><tr><td>944143.World Health Organization. WHO advises that ivermectin only be used to treat COVID-
19 within clinical trials. <a href=" https:="" news-room="" who-<="" www.who.int=""> 946946advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials. Published 2021. Updated 03/31/2021. Accessed 08/25/2021.948144.ACTIV-6: COVID-19 Study of Repurposed Medications.
94519 within clinical trials.

- 974 Figure and Table Legends:
- 975 Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—
- 976 study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and
- 977 Prevention, RCT: Randomized controlled trial, WHO: World Health Organization
- 978 Figure 2: Meta-analysis for Ivermectin use and overall Mortality
- 979 Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and
- 980 hospitalized patients
- 981 Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in
- 982 RCTs as per Cochrane's criteria
- 983 Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical
- 984 ventilation and Adverse events
- 985 Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve
- 986 viral clearance, Need for hospitalization and Duration of hospital stay
- 987 e-figure 1 Sensitivity analysis excluding Lima-morales et al: Mortality in Clinical trials
- 988 e-figure 2 Sensitivity analysis excluding Vallejos et al: Mortality in Therapeutic RCTs:
- 989 Mild-Moderate COVID-19
- 990 e-figure 3 Sensitivity analysis excluding Soto-Becerra et al: Mortality in observational
- 991 studies
- 992 e-figure 4 Sensitivity analysis excluding Soto-Becerra et al: Mortality in hospitalized
- 993 patients-Overall
- 994 e-figure 5 Sensitivity analysis excluding Abd-elsalam et al: Mortality in hospitalized
- 995 patients by study design RCTs: Mild-Moderate COVID-19

- 996 e-figure 6 Sensitivity Analysis excluding Soto-Becerra et al: Mortality in inpatient
- 997 observational studies
- 998 e-figure 7 Pooled Analysis for Mortality
- 999 e-figure 8 Pooled analysis of need for ICU admission
- 1000 e-figure 9 Pooled analysis of Mechanical Ventilation
- 1001 e-figure 10 Pooled Analysis of Adverse events
- 1002 e-figure 11 Sensitivity Analysis excluding Maurya et al : Viral Clearance
- 1003 e-figure 12 Sensitivity Analysis excluding Khan et al : Time to achieve Viral Clearance
- 1004 e-figure 13 Sensitivity Analysis excluding Mahmud et al : Need for hospitalization
- 1005 e-figure 14 Sensitivity Analysis excluding Gonzalez et al : Duration of hospital stay
- 1006 e-figure 15 Funnel Plot overall mortality
- 1007 e-figure 16 Funnel Plot Mortality in Clinical Trials
- 1008 e-figure 17 Funnel Plot Mortality in RCTs: Mild/Moderate COVID-19
- 1009 e-figure 18 Funnel Plot Mortality in RCTs: Severe/Critical COVID-19
- 1010 e-figure 19 Funnel Plot Mortality in Observational studies
- 1011 e-figure 20 Funnel Plot Mortality in Hospitalized patient overall
- 1012 e-figure 21 Funnel Plot Mortality in Inpatient RCTs: Mild-Moderate COVID-19
- 1013 e-figure 22 Funnel Plot Mortality in Inpatient RCTs: Severe/Critical COVID-19
- 1014 e-figure 23 Funnel Plot Mortality in Inpatient Observational studies
- 1015 e-figure 24 Funnel Plot for Mortality with Ivermectin Monotherapy as per Cochrane's
- 1016 Criteria
- 1017 e-figure 25 Funnel Plot Need for ICU Admission
- 1018 e-figure 26 Funnel Plot Need for Mechanical Ventilation
- 1019 e-figure 27 Funnel Plot Adverse event
- 1020 e-figure 28 Funnel Plot Need for Hospitalization

- 1021 e-figure 29 Funnel Plot duration of Hospital stay
- 1022 e-figure 30 Funnel Plot Incidence of Viral Clearance
- 1023 e-figure 31 Funnel Plot Time to achieve viral clearance
- 1024 e-table 1. Study characteristic table for all included studies
- 1025 e-table 2. Cochrane Risk of bias assessment of the trials included in the study
- 1026 e-table 3. Correlation of quality measures with estimates of treatment effects assessment of
- 1027 the trials those were included in the study
- 1028 e-table 4. NIH quality assessment Tool for case series included in the study
- 1029 e-table 5. NIH Quality Assessment of Case-Control Studies
- 1030 e-table 6. NIH Quality Assessment of Observational Cohort and Cross-Sectional Studies
- 1031 e-table 7. Certainty of the evidence (GRADE) Profile at Outcome Level
- 1032 e-table 8. Ongoing clinical trials
- 1033

- 1034 Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow—
- 1035 study inclusion. ICU: Intensive Care Unit, CDC: Centers for Disease Control and
- 1036 Prevention, RCT: Randomized controlled trial, WHO: World Health Organization



It is made available under a CC-BY-NC-ND 4.0 International license .

1037 Figure 2: Meta-analysis for Ivermectin use and overall Mortality

1038 Figure 2A: Mortality Overall

	lverme		No lverm			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total		M-H, Random, 95% Cl	M-H, Random, 95% Cl
Abd-elsalam et al	3	82	4	82	4.5%	0.74 [0.16, 3.42]	
Ahsan et al	17	110	17	55	6.9%	0.41 [0.19, 0.88]	
Babalola et al	0	42	0	20		Not estimable	
Budhiraja et al	0	34	103	942	2.1%	0.12 [0.01, 1.93]	·
Cadegiani et al	0	110	2	137	1.8%	0.25 [0.01, 5.16]	
Chaccour et al	0	12	0	12		Not estimable	
Chahla et al	0	110	0	62		Not estimable	
Elalfy et al	0	62	0	51		Not estimable	
Galan et al	12	53	25	115	6.9%	1.05 [0.48, 2.30]	
Эhooi et al	3	15	77	1020	5.2%	3.06 [0.85, 11.08]	
Gonzalez et al	5	36	8	70	5.5%	1.25 [0.38, 4.14]	
Gorial et al	0	16	2	71	1.8%	0.84 [0.04, 18.39]	
Guzman et al	48	122	39	74	7.5%	0.58 [0.32, 1.04]	
Hashim et al	2	70	6	70	4.2%	0.31 [0.06, 1.61]	-
Khan et al	1	115	9	133	3.2%	0.12 [0.02, 0.97]	
≺irti et al	0	55	4	57	1.9%	0.11 [0.01, 2.04]	•
Lima-Morales et al	13	434	52	287	7.4%	0.14 [0.07, 0.26]	_ _
Lopez-Medina et al	0	200	1	198	1.7%	0.33 [0.01, 8.11]	
Loué et al	1	10	5	15	2.7%	0.22 [0.02, 2.28]	
Mahmud et al	0	183	3	180	1.9%	0.14 [0.01, 2.69]	· · · · · · · · · · · · · · · · · · ·
Mohan et al	0	100	0	52		Not estimable	
Mourya et al	0	50	0	50		Not estimable	
Niaee et al	4	120	11	60	5.5%	0.15 [0.05, 0.51]	
Okumus et al	6	30	9	30	5.5%	0.58 [0.18, 1.91]	
Rajter et al	26	173	27	107	7.5%	0.52 [0.29, 0.96]	
Shahbaznejad et al	1	35	0	34	1.7%	3.00 [0.12, 76.24]	
Soto-Becerra et al	132	561	940	5122	8.4%	1.37 [1.11, 1.68]	-
Vallejos et al	4	250	3	251	4.5%	1.34 [0.30, 6.07]	
Veerapaneni et al	1	50	0	50	1.7%	3.06 [0.12, 76.95]	
Total (95% CI)		3240		9407	100.0%	0.54 [0.34, 0.86]	◆
Total events	279		1347				
Heterogeneity: Tau² = Test for overall effect:				(P < 0.0	0001); I ^z :	= 75%	0.01 0.1 1 10 10 Ivermectin No Ivermectin

1039

1040 Figure 2B Sensitivity analysis Mortality Overall excluding Soto-Becerra et al

Study or Subgroup	lverme Events		No lverm Events	Total	Weight	Odds Ratio M-H, Random, 95% Cl	Odds Ratio M-H, Random, 95% Cl
Abd-elsalam et al	3	82	4	82	4.6%	0.74 [0.16, 3.42]	
Ahsan et al	17	110	17	55	8.3%	0.41 [0.19, 0.88]	
Babalola et al	0	42	0	20	0.5 %	Not estimable	
Budhiraja et al	0	34	103	942	1.9%	0.12 [0.01, 1.93]	•
Cadegiani et al	0	110	2	137	1.5%	0.25 [0.01, 5.16]	·
Chaccour et al	0	12	0	12	1.0 %	Not estimable	
Chahla et al	0	110	0	62		Not estimable	
Elalfyetal	0	62	0	51		Not estimable	
⊂ialiyetai Galan etal	12	53	25	115	8.3%	1.05 [0.48, 2.30]	
Ghooi et al	3	15	25	1020	0.3% 5.5%	3.06 [0.85, 11.08]	
Gonzalez et al	з 5	36	8	70	5.5% 6.0%	1.25 [0.38, 4.14]	
Gorial et al	5 0	30 16	2	70	1.6%	0.84 [0.04, 18.39]	
Guzman et al	48	122	39	74	9.4%	0.58 [0.32, 1.04]	
Hashim et al	40	70		70	9.4%	0.31 [0.06, 1.61]	
Hashim etal Khan etal	2	115	9	133	4.2%	0.12 [0.02, 0.97]	
Kinti et al	0	55	9	57	1.7%	0.12 [0.02, 0.97]	•
lima-Morales et al	13	434	52	287	9.2%	0.14 [0.07, 0.26]	·
Lopez-Medina et al	13	200	1	198	9.2%	0.33 [0.01, 8.11]	
Lopez-medina et al Loué et al	1	200 10	5	198	2.5%	0.22 [0.02, 2.28]	
Loue et al Mahmud et al	0	183	3	180	2.5%		· · · · · · · · · · · · · · · · · · ·
	0		3	180	1.7%	0.14 [0.01, 2.69]	•
Mohan et al	0	100	0			Not estimable Not estimable	
Mourya et al	4	50	11	50	C 000		
Niaee et al		120 30		60	6.0%	0.15 [0.05, 0.51]	
Okumus et al	6 26	173	9 27	30	6.0% 9.3%	0.58 [0.18, 1.91]	
Rajter et al	20	35		107	9.3%	0.52 [0.29, 0.96]	
Shahbaznejad et al	•		0	34		3.00 [0.12, 76.24]	
Soto-Becerra et al	132	561	940 3	5122	0.0% 4.6%	1.37 [1.11, 1.68]	
Vallejos et al	4	250 50	-	251		1.34 [0.30, 6.07]	
Veerapaneni et al	1	50	0	50	1.5%	3.06 [0.12, 76.95]	
Total (95% CI)		2679		4285	100.0%	0.49 [0.32, 0.75]	◆
Total events	147		407				
Heterogeneity: Tau² =				(P = 0.0	02); I² = 5	2%	0.01 0.1 1 10 1
Fest for overall effect:	Z = 3.28 (P = 0.0	01)				Ivermectin No Ivermectin

It is made available under a CC-BY-NC-ND 4.0 International license .

1042 Figure 3: Subgroup analysis for Ivermectin use and mortality by study design and

1043 hospitalized patients

1044 Figure 3A Subgroup analysis by study designs- Mortality in Clinical trials

lvermectin		No lvermectin			Odds Ratio	Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Abd-elsalam et al	3	82	4	82	8.4%	0.74 [0.16, 3.42]	
Babalola et al	0	42	0	20		Not estimable	
Chaccour et al	0	12	0	12		Not estimable	
Chahla et al	0	110	0	62		Not estimable	
Elalfy et al	0	62	0	51		Not estimable	
Galan et al	12	53	25	115	13.0%	1.05 [0.48, 2.30]	_
Gonzalez et al	5	36	8	70	10.3%	1.25 [0.38, 4.14]	
Gorial et al	0	16	2	71	3.4%	0.84 [0.04, 18.39]	
Hashim et al	2	70	6	70	7.9%	0.31 [0.06, 1.61]	
Kirti et al	0	55	4	57	3.7%	0.11 [0.01, 2.04]	• • • · · · · · · · · · · · · · · · · ·
Lima-Morales et al	13	434	52	287	13.9%	0.14 [0.07, 0.26]	_
Lopez-Medina et al	0	200	1	198	3.2%	0.33 [0.01, 8.11]	
Mahmud et al	0	183	3	180	3.6%	0.14 [0.01, 2.69]	← · · · · · · · · · · · · · · · · · · ·
Mohan et al	0	100	0	52		Not estimable	
Niaee et al	4	120	11	60	10.4%	0.15 [0.05, 0.51]	
Okumus et al	6	30	9	30	10.4%	0.58 [0.18, 1.91]	
Shahbaznejad et al	1	35	0	34	3.2%	3.00 [0.12, 76.24]	
Vallejos et al	4	250	3	251	8.5%	1.34 [0.30, 6.07]	
Total (95% CI)		1890		1702	100.0%	0.47 [0.25, 0.90]	•
Total events	50		128				
Heterogeneity: Tau ² =	0.68; Chi	i ^z = 29.3	34, df = 12	(P = 0.0	04); I² = 5	9%	
Test for overall effect:				0.01 0.1 1 10 10 Ivermectin No Ivermectin			

1046 Figure 3B Subgroup analysis by study designs- Mortality in Therapeutic RCTs: Mild-

1047 Moderate COVID-19

	lvermectin		No lvermectin			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Abd-elsalam et al	3	82	4	82	24.0%	0.74 [0.16, 3.42]	
Babalola et al	0	42	0	20		Not estimable	
Chaccour et al	0	12	0	12		Not estimable	
Chahla et al	0	110	0	62		Not estimable	
Hashim et al	0	48	0	48		Not estimable	
Kirti et al	0	55	4	57	11.7%	0.11 [0.01, 2.04]	· · · · · · · · · · · · · · · · · · ·
Lopez-Medina et al	0	200	1	198	10.4%	0.33 [0.01, 8.11]	
Mahmud et al	0	183	3	180	11.6%	0.14 [0.01, 2.69]	• • • · · · · · · · · · · · · · · · · ·
Mohan et al	0	100	0	52		Not estimable	
Niaee et al	1	103	10	55	18.0%	0.04 [0.01, 0.36]	← ■
Shahbaznejad et al	0	28	0	31		Not estimable	
Vallejos et al	4	250	3	251	24.3%	1.34 [0.30, 6.07]	
Total (95% CI)		1213		1048	100.0%	0.31 [0.09, 1.04]	
Total events	8		25				
Heterogeneity: Tau ² =	0.97; Chi	² = 9.09	9, df = 5 (P	= 0.11);	I² = 45%		
Test for overall effect:	Z=1.90(P = 0.0	6)				0.01 0.1 1 10 100 Ivermectin No Ivermectin

1048

1045

1049


It is made available under a CC-BY-NC-ND 4.0 International license .

1051 Figure 3C Subgroup analysis by study designs- Mortality in Therapeutic RCTs:

1052 Severe/Critical COVID-19

lvermectin		ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events Total		Events Tota		Weight	M-H, Random, 95% CI	I M-H, Random, 95% CI
Galan et al	12	53	25	115	45.3%	1.05 [0.48, 2.30]]
Gonzalez et al	5	36	8	70	19.3%	1.25 [0.38, 4.14]	j — =
Hashim et al	2	22	6	22	9.2%	0.27 [0.05, 1.50]	
Niaee et al	3	17	1	5	4.3%	0.86 [0.07, 10.67]]
Okumus et al	6	30	9	30	19.6%	0.58 [0.18, 1.91]]
Shahbaznejad et al	1	7	0	3	2.3%	1.62 [0.05, 51.11]	1
Total (95% CI)		165		245	100.0%	0.86 [0.51, 1.45]	•
Total events	29		49				
Heterogeneity: Tau ² =	= 0.00; Chi	i ^z = 2.94	l, df = 5 (P	= 0.71);	I² = 0%		
Test for overall effect: Z = 0.58 (P = 0			6)				0.01 0.1 1 10 100 Ivermectin No Ivermectin

1054 Figure 3D: Subgroup analysis by study designs- Mortality in observational studies



1056 Figure 3E: Mortality in hospitalized patients-Overall

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Abd-elsalam et al	3	82	4	82	5.1%	0.74 [0.16, 3.42]	· · · · · · · · · · · · · · · · · · ·
Ahsan et al	17	110	17	55	9.3%	0.41 [0.19, 0.88]	
Budhiraja et al	0	34	103	942	2.1%	0.12 [0.01, 1.93]	· • · · · · · · · · · · · · · · · · · ·
Galan et al	12	53	25	115	9.2%	1.05 [0.48, 2.30]	
Ghooi et al	3	15	77	1020	6.2%	3.06 [0.85, 11.08]	↓ →
Gonzalez et al	5	36	8	70	6.6%	1.25 [0.38, 4.14]	
Gorial et al	0	16	2	71	1.8%	0.84 [0.04, 18.39]	· · · · · · · · · · · · · · · · · · ·
Guzman et al	48	122	39	74	10.6%	0.58 [0.32, 1.04]	
Hashim et al	2	22	6	22	4.3%	0.27 [0.05, 1.50]	
Khan et al	1	115	9	133	3.3%	0.12 [0.02, 0.97]	
Kirti et al	0	55	4	57	1.9%	0.11 [0.01, 2.04]	· • · · · · · · · · · · · · · · · · · ·
Mohan et al	0	100	0	52		Not estimable	!
Niaee et al	4	120	11	60	6.7%	0.15 [0.05, 0.51]	
Okumus et al	6	30	9	30	6.7%	0.58 [0.18, 1.91]	
Rajter et al	26	173	27	107	10.5%	0.52 [0.29, 0.96]	
Shahbaznejad et al	1	35	0	34	1.6%	3.00 [0.12, 76.24]	
Soto-Becerra et al	132	561	940	5122	12.6%	1.37 [1.11, 1.68]	
Veerapaneni et al	1	50	0	50	1.6%	3.06 [0.12, 76.95]	
Total (95% CI)		1729		8096	100.0%	0.65 [0.42, 1.00]	▲
Total events	261		1281				
Heterogeneity: Tau ² =	= 0.39; Ch	i ² = 47.2	24. df = 16	(P < 0.0	001); I ^z =	66%	
Test for overall effect	•		•		21.5		0.01 0.1 1 10 10 Ivermectin No Ivermectin

1057


1053

It is made available under a CC-BY-NC-ND 4.0 International license .

1058 Figure 3F: Mortality in hospitalized patients by study design RCTs-Mild-Moderate COVID-1059 19

lvermecti		ctin	No lverm	ectin	Odds Ratio			Odds Ratio		
Study or Subgroup	Events	vents Total Events Total Weight M-H, Random, 95%		M-H, Random, 95% Cl	M-H, Random, 95% Cl					
Abd-elsalam et al	3	82	4	82	41.4%	0.74 [0.16, 3.42]				
Kirti et al	0	55	4	57	24.6%	0.11 [0.01, 2.04]	←			
Mohan et al	0	100	0	52		Not estimable				
Niaee et al	1	103	10	55	34.0%	0.04 [0.01, 0.36]	←			
Shahbaznejad et al	0	28	0	31		Not estimable				
Total (95% CI)		368		277	100.0%	0.18 [0.02, 1.25]			-	
Total events	4		18							
Heterogeneity: Tau ² =	1.80; Chi	P = 5.12	2, df = 2 (P	= 0.08);	I² = 61%					100
Test for overall effect:			• •				0.01		1 10 No Ivermectin	100

Figure 3G: Mortality in hospitalized patients by study design RCTs- Severe/Critical COVID 1062 19



1063


1060

1064 Figure 3H: Mortality in hospitalized patients by study design observational studies

	Ivermectin No Ivermectin					Odds Ratio		Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl		
Ahsan et al	17	110	17	55	16.5%	0.41 [0.19, 0.88]				
Budhiraja et al	0	34	103	942	4.0%	0.12 [0.01, 1.93]	•			
Ghooi et al	3	15	77	1020	11.3%	3.06 [0.85, 11.08]		+		
Guzman et al	48	122	39	74	18.6%	0.58 [0.32, 1.04]				
Khan et al	1	115	9	133	6.3%	0.12 [0.02, 0.97]				
Rajter et al	26	173	27	107	18.4%	0.52 [0.29, 0.96]				
Soto-Becerra et al	132	561	940	5122	21.8%	1.37 [1.11, 1.68]		-		
Veerapaneni et al	1	50	0	50	3.1%	3.06 [0.12, 76.95]				
Total (95% CI)		1180		7503	100.0%	0.70 [0.38, 1.30]		•		
Total events	228		1212							
Heterogeneity: Tau ² =	= 0.44; Chi	i ^z = 30.8	36, df = 7 (P < 0.00	01); I² = 7	7%				
Test for overall effect:	Z=1.13 ((P = 0.2	6)				0.01	0.1 1 10 10 Ivermectin No Ivermectin		

1067 Figure 4 Effect of Ivermectin Monotherapy compared with Placebo/Standard of Care in RCTs

1068 as per Cochrane's criteria




1069

1070 Figure 5: Meta-analysis for Ivermectin use and need for ICU admission, mechanical


1071 ventilation and Adverse events

1072 Figure 5A Need for ICU admission



1073

1074 Figure 5B Sensitivity Analysis excluding Galan et al : Need for ICU admission



It is made available under a CC-BY-NC-ND 4.0 International license .

1076 Figure 5C Need for Mechanical ventilation

	Ivermectin		Ivermectin No Iverm			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Abd-elsalam et al	3	82	3	82	4.9%	1.00 [0.20, 5.11]	
Cadegiani et al	0	110	9	137	1.6%	0.06 [0.00, 1.06]	· · · · · · · · · · · · · · · · · · ·
Camprubi et al	3	13	5	13	4.5%	0.48 [0.09, 2.65]	
Galan et al	12	53	24	115	21.1%	1.11 [0.51, 2.43]	_
Kirti et al	1	55	5	57	2.7%	0.19 [0.02, 1.70]	
Kroleweicki et al	1	30	0	15	1.2%	1.58 [0.06, 41.03]	
Lima-Morales et al	8	434	11	287	15.3%	0.47 [0.19, 1.19]	
Mohan et al	0	100	0	52		Not estimable	
Pott-Junior et al	1	27	1	4	1.4%	0.12 [0.01, 2.36]	· · · · · · · · · · · · · · · · · · ·
Rajter et al	36	173	26	107	39.4%	0.82 [0.46, 1.45]	
Shahbaznejad et al	2	35	1	34	2.2%	2.00 [0.17, 23.14]	
Vallejos et al	4	250	3	251	5.7%	1.34 [0.30, 6.07]	
Total (95% CI)		1362		1154	100.0%	0.75 [0.52, 1.08]	•
Total events	71		88				
Heterogeneity: Tau ² =	: 0.00; Chi	* = 9.89	9, df = 10 (P = 0.45); I ^z = 0%		
Test for overall effect:	Z=1.56 ((P = 0.1	2)				0.01 0.1 i 10 100 Ivermectin No Ivermectin

1077

1079

1078 Figure 5D Sensitivity Analysis excluding Galan et al : Need for Mechanical ventilation

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio			
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% CI			
Abd-elsalam et al	3	82	3	82	6.2%	1.00 [0.20, 5.11]				
Cadegiani et al	0	110	9	137	2.0%	0.06 [0.00, 1.06]	← → → → → → → → → → → → → → → → → → → →			
Camprubi et al	3	13	5	13	5.7%	0.48 [0.09, 2.65]				
Galan et al	12	53	24	115	0.0%	1.11 [0.51, 2.43]				
Kirti et al	1	55	5	57	3.5%	0.19 [0.02, 1.70]				
Kroleweicki et al	1	30	0	15	1.6%	1.58 [0.06, 41.03]				
Lima-Morales et al	8	434	11	287	19.3%	0.47 [0.19, 1.19]				
Mohan et al	0	100	0	52		Not estimable				
Pott-Junior et al	1	27	1	4	1.8%	0.12 [0.01, 2.36]	· · · · · · · · · · · · · · · · · · ·			
Rajter et al	36	173	26	107	50.0%	0.82 [0.46, 1.45]				
Shahbaznejad et al	2	35	1	34	2.7%	2.00 [0.17, 23.14]				
Vallejos et al	4	250	3	251	7.3%	1.34 [0.30, 6.07]				
Total (95% CI)		1309		1039	100.0%	0.68 [0.45, 1.01]	◆			
Total events	59		64							
Heterogeneity: Tau ² =	: 0.00; Chi	i ^z = 8.67	7, df = 9 (P	= 0.47);	I ² = 0%					
Test for overall effect:	Z=1.89 ((P = 0.0	6)				0.01 0.1 1 10 10 Ivermectin No Ivermectin			

1080 Figure 5E Adverse events

	lverme		No lverm			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Afsaretal	0	41	0	54		Not estimable	
Ahmed et al	0	45	0	23		Not estimable	
Babalola et al	0	42	0	20		Not estimable	
Biber et al	2	47	1	42	1.1%	1.82 [0.16, 20.85]	
Bukhari et al	0	41	0	45		Not estimable	
Camprubi et al	3	13	4	13	2.1%	0.68 [0.12, 3.87]	
Chaccour et al	5	12	5	12	2.5%	1.00 [0.20, 5.07]	
Chowdhury et al	19	60	26	56	11.3%	0.53 [0.25, 1.14]	
Espitia-Hernandez et al	3	28	0	7	0.7%	2.06 [0.10, 44.48]	
Galan et al	8	53	16	115	7.7%	1.10 [0.44, 2.76]	_
Gorial et al	0	16	0	71		Not estimable	
Huvemec group	0	50	0	50		Not estimable	
Kroleweicki et al	13	30	5	15	3.9%	1.53 [0.42, 5.58]	-
Lopez-Medina et al	156	200	163	198	25.7%	0.76 [0.46, 1.25]	
Mahmud et al	9	185	0	180	0.8%	19.43 [1.12, 336.37]	
Mohan et al	14	100	6	52	6.2%	1.25 [0.45, 3.47]	-
Mourya et al	0	50	0	50		Not estimable	
Okumus et al	0	30	3	30	0.7%	0.13 [0.01, 2.61]	←
Pott-Junior et al	7	27	2	4	1.4%	0.35 [0.04, 2.98]	
Shahbaznejad et al	0	35	0	34		Not estimable	
Vallejos et al	45	250	53	251	31.8%	0.82 [0.53, 1.28]	
Veerapaneni et al	8	50	4	50	4.0%	2.19 [0.61, 7.81]	
Total (95% CI)		1405		1372	100.0%	0.87 [0.67, 1.13]	•
Total events	292		288				
Heterogeneity: Tau ² = 0.0	0; Chi [≥] = 1	3.14, d	f = 13 (P =	0.44); l ^a	²= 1%		
Test for overall effect: Z =							0.01 0.1 1 10 10
	· · V						Ivermectin No Ivermectin

It is made available under a CC-BY-NC-ND 4.0 International license .

1083 Figure 5F Sensitivity Analysis excluding Veerapaneni et al : Adverse events

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Afsar et al	0	41	0	54		Not estimable	
Ahmed et al	0	45	0	23		Not estimable	
Babalola et al	0	42	0	20		Not estimable	
Biber et al	2	47	1	42	1.1%	1.82 [0.16, 20.85]	
Bukhari et al	0	41	0	45		Not estimable	
Camprubi et al	3	13	4	13	2.2%	0.68 [0.12, 3.87]	
Chaccour et al	5	12	5	12	2.5%	1.00 [0.20, 5.07]	
Chowdhury et al	19	60	26	56	11.6%	0.53 [0.25, 1.14]	
Espitia-Hernandez et al	3	28	0	7	0.7%	2.06 [0.10, 44.48]	
Galan et al	8	53	16	115	7.8%	1.10 [0.44, 2.76]	_
Gorial et al	0	16	0	71		Not estimable	
Huvemec group	0	50	0	50		Not estimable	
Kroleweicki et al	13	30	5	15	4.0%	1.53 [0.42, 5.58]	+•
Lopez-Medina et al	156	200	163	198	27.0%	0.76 [0.46, 1.25]	
Mahmud et al	9	185	0	180	0.8%	19.43 [1.12, 336.37]	+
Mohan et al	14	100	6	52	6.3%	1.25 [0.45, 3.47]	-
Mourya et al	0	50	0	50		Not estimable	
Okumus et al	0	30	3	30	0.7%	0.13 [0.01, 2.61]	· · · · · · · · · · · · · · · · · · ·
Pott-Junior et al	7	27	2	4	1.4%	0.35 [0.04, 2.98]	
Shahbaznejad et al	0	35	0	34		Not estimable	
Vallejos et al	45	250	53	251	33.8%	0.82 [0.53, 1.28]	
Veerapaneni et al	8	50	4	50	0.0%	2.19 [0.61, 7.81]	
Total (95% CI)		1355		1322	100.0%	0.84 [0.65, 1.08]	•
Total events	284		284				
Heterogeneity: Tau² = 0.0			f=12 (P=	0.53); l ^a	²= 0%		0.01 0.1 1 10 100
Test for overall effect: Z =	1.35 (P =	U.18)					Ivermectin No Ivermectin

1084

1085 Figure 6: Meta-analysis for Ivermectin use and need for Viral Clearance, Time to achieve

1086 viral clearance, Need for hospitalization and Duration of hospital stay

1087 Figure 6A Viral Clearance

	lverme	ctin	No lverm	ectin		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
Ahmed et al	31	45	9	23	6.0%	3.44 [1.21, 9.83]	
Aref et al	54	57	43	57	5.5%	5.86 [1.58, 21.71]	
Biber et al	40	47	29	42	6.0%	2.56 [0.91, 7.22]	
Bukhari et al	37	41	20	45	5.7%	11.56 [3.53, 37.91]	
Camprubi et al	8	13	9	13	5.0%	0.71 [0.14, 3.61]	
Chaccour et al	0	12	0	12		Not estimable	
Chowdhury et al	60	60	54	56	2.8%	5.55 [0.26, 118.18]	
Elalfy et al	55	62	7	51	5.9%	49.39 [16.11, 151.39]	_
Espitia-Hernandez et al	28	28	0	7	2.0%	855.00 [15.63, 46756.26]	
Kinti et al	13	55	18	57	6.3%	0.67 [0.29, 1.55]	- _
Kishoria et al	8	19	6	13	5.3%	0.85 [0.20, 3.51]	
Loué et al	10	10	15	15		Not estimable	
Mahmud et al	169	183	144	180	6.6%	3.02 [1.57, 5.82]	
Mohan et al	29	72	16	42	6.4%	1.10 [0.50, 2.39]	_ -
Mourya et al	45	50	3	50	5.2%	141.00 [31.82, 624.74]	
Okumus et al	14	16	3	8	4.2%	11.67 [1.49, 91.54]	· · · · · · · · · · · · · · · · · · ·
Podder et al	18	20	19	20	3.5%	0.47 [0.04, 5.69]	
Pott-Junior et al	17	27	2	4	4.1%	1.70 [0.21, 14.02]	
Rahman et al	167	200	163	200	6.7%	1.15 [0.69, 1.93]	_ _
Samaha et al	12	50	0	50	3.1%	32.79 [1.88, 571.25]	
Vallejos et al	212	250	221	251	6.7%	0.76 [0.45, 1.27]	
Veerapaneni et al	9	10	9	10	3.0%	1.00 [0.05, 18.57]	
Total (95% CI)		1327		1206	100.0%	3.52 [1.81, 6.86]	•
Total events	1036		790				-
Heterogeneity: Tau² = 1.6 Test for overall effect: Z =				< 0.000	01); I² = 8	5%	0.01 0.1 1 10 10 Ivermectin No Ivermectin

It is made available under a CC-BY-NC-ND 4.0 International license .


1089 Figure 6B Time to achieve viral clearance

	Ivermectin			No Iv	ermec	tin		Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Random, 95% CI	
Ahmed et al (IVM)	9.7	4.5	22	12.7	3.35	23	12.3%	-3.00 [-5.33, -0.67]		+	
Aref et al	8.3	2.8	57	12.9	4.3	57	12.8%	-4.60 [-5.93, -3.27]		-	
Babalola et al	5.33	3.12	42	9.15	7.42	20	11.6%	-3.82 [-7.21, -0.43]		-	
Cadegiani et al	16.036	6.5	110	22.2	6	137	12.7%	-6.16 [-7.74, -4.59]		•	
Chowdhury et al	8.93	1.29	60	9.26	2.27	54	13.0%	-0.33 [-1.02, 0.36]			
Gorial et al	8	4.06	16	12.33	3.78	71	12.4%	-4.33 [-6.51, -2.15]		-	
Khan et al	4.6	1.5	115	14.6	3.75	133	13.0%	-10.00 [-10.69, -9.31]		-	
Pott-Junior et al	5.16	2.74	27	5.67	2.18	4	12.3%	-0.51 [-2.88, 1.86]		†	
Total (95% CI)			449			499	100.0%	-4.12 [-7.59, -0.65]		•	
Heterogeneity: Tau ² =	Heterogeneity: Tau ² = 24.09; Chi ² = 396.19, df = 7 (P < 0.00001); l ² = 98%									<u> </u>	
Heterogeneity: $1au^2 = 24.03$; $Ch^2 = 396.19$; $dt = 7$ (P < 0.00001); P = 98% Test for overall effect: Z = 2.33 (P = 0.02)										-50 0 (Ivermectin No Iverme	50 100 ctin

1090

1092

1091 Figure 6C Need for hospitalization



1093 Figure 6D Duration of hospital stay

	lver	mecti	n	No Iv	ermec	tin		Mean Difference	Mean Difference			
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl		IV, Random, 9	5% CI	
Abd-elsalam et al	8.82	4.94	82	10.97	5.28	82	11.1%	-2.15 [-3.72, -0.58]		•		
Ahmed et al (IVM)	9.6	4.5	22	9.7	3.35	23	10.2%	-0.10 [-2.43, 2.23]		+		
Gonzalez et al (IVM vs placebo)	7	5.4	36	5.33	2.3	37	10.7%	1.67 [-0.24, 3.58]		+		
Gorial et al	7.62	2.75	16	13.22	5.9	71	10.7%	-5.60 [-7.52, -3.68]		•		
Khan et al	8.66	2.25	115	15.33	5.24	133	11.6%	-6.67 [-7.65, -5.69]				
Niaee et al	6.93	2.74	120	8.53	3.92	60	11.5%	-1.60 [-2.71, -0.49]		•		
Rajter et al	8.1	6.95	173	7	4.5	107	11.3%	1.10 [-0.24, 2.44]		· · · · · ·		
Shahbaznejad et al	6.9	3.1	35	8.3	3.3	34	11.2%	-1.40 [-2.91, 0.11]		•		
Veerapaneni et al	6.67	2.01	50	7.89	2.35	50	11.7%	-1.22 [-2.08, -0.36]		•		
Total (95% CI)			649			597	100.0%	-1.80 [-3.69, 0.08]		•		
Heterogeneity: Tau ² = 7.67; Chi ² = 141.10, df = 8 (P < 0.00001); I ² = 94%										-50 0	50	100
Test for overall effect: Z = 1.88 (P	= 0.06)									Ivermectin No	lvermectin	